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Abstract 
Aim: To assess SELDI-TOF MS technology as a tool for biomarker discovery in the 
stool and serum of colorectal cancer patients.  
Materials and Methods:  
1.Initially a technique of analysis was developed and optimised using tumour samples 
and matched normal mucosa, obtained from the Tayside Tissue Bank. These samples 
were then analysed using SELDI on a PBS II Protein Chip Mass Spectrometer to 
identify abundant proteins.  
2. A technique of stool preparation and subsequent SELDI analysis was developed and 
then optimised (CM10 chip at pH4) to allow comparison of faecal samples from cancer 
and controls. Faecal samples were then collected from cancer patients and controls and 
analysed. In addition, FOB testing was carried out on all stool samples from cancer and 
controls and subgroup analysis of spectras was performed controlling for FOB status.   
3. A test set of cancer and normal serum samples was used to optimise the method of 
analysis using 4 different chip surfaces at differing pH.  Serum samples were collected 
from cancer patients and normal controls and were analysed on the H50 chip. Serum 
was then depleted of major proteins in an attempt to improve the detection of peaks.  
The mass spectra from each sample type were compared to identify any common protein 
peaks. 
Results:  
1. Tumour analysis methods were optimised using an initial 4 samples of tumour and 
normal mucosa. Analysis of 8 further paired samples showed protein peaks at 2826, 
3374, 3444, 3489 and 10854 Da which were abundant in tumour and reduced in the 
normal mucosa.  
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2. In serum analysis the initial experiment of 10 cancer versus 10 normal revealed 4 
peaks on the H50 chip (3479, 3364, 3434, 3700 Da) that had significantly higher mass to 
charge ratios in cancer. The experiment was repeated on the H50 chip using 92 cancers 
and 92 controls and 5 different peaks were identified (7901, 8124, 8566, 8799 and 17 
409Da) as being significant but these had higher mass to charge ratios in the controls. 
After depletion of the serum samples of albumin, transferrin, haptoglobin, anti-trypsin, 
IgG and IgA SELDI-TOF analysis showed a greatly reduced profile that yielded no 
meaningful spectra.  
3. Stool analysis revealed 5 protein peaks (4633, 16511, 33423, 37087 and 47026 Da) in 
colorectal cancer patients, which were absent in stools from controls with a sensitivity of 
83% when using all 5 peaks. Degradation of the spectra was observed after prolonged 
storage of stool samples. 
Conclusions: A method of stool analysis has been developed that yielded valid peaks 
differentiating between cancer and normal, which warrant further research through 
protein identification.  Serum analysis was not reproducible across experiments and 
depletion of major proteins failed to reveal the sub-proteome raising doubts about 
whether discovery-based serum proteomics can accurately detect cancer. SELDI-TOF 
was not able to demonstrate that any of the peaks present in the tumour analysis were 
present in the stool or the serum samples.  
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CHAPTER 1 
INTRODUCTION 
Part 1  Colorectal cancer 
1.1.1.1 Colorectal cancer  
Colorectal cancer is the third most common cancer diagnosed in the United Kingdom and 
accounts for 10% of all cancer deaths(Mayor 1998).  35 300 cases were diagnosed in England 
and Wales in 2000, accounting for 13% of all cancers diagnosed that year and 842 men and 
713 women died of the disease in Scotland in 2002(Statistics 2005).  Incidence is higher in 
males and there is also considerable variation amongst different ethnic groups. It is a disease 
of the developed world and despite an increasing risk in many countries, overall survival 
rates are improving(Scholefield, Moss et al. 2002).  Survival correlates with stage and ranges 
from 95% five year survival for Dukes’ A disease, 80% Dukes’ B and 45% for Dukes’ C 
cancer, so that the benefits of diagnosing colorectal  cancers early are easily 
appreciated(Coleman 2004). 
Sporadic colorectal cancers are more common than familial cases and account for almost 
90% of diagnosed tumours(Hardy, Meltzer et al. 2000).  Genetic and environmental factors 
play an important role and although many of these lifestyle and environmental factors 
especially those associated with lifestyle can be controlled by the individual, there is also a 
strong association with previous colorectal polyps and a familial association that is not 
accounted for by the same genetic mechanism as the hereditary colorectal cancers. Familial 
adenomatous polyposis (FAP), previously known as polyposis coli and part of the spectrum 
of genetic changes that constitute Gardner’s Syndrome (FAP with extra colonic 
manifestations) is caused by mutations in the APC gene. This autosomal dominant disease 
leads to the development of hundreds of adenomas in the colon and if left untreated will 
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lead to the development of colorectal cancer by middle age in almost all patients. Removal of 
the colorectum does not entirely protect the patients from the mortality and morbidity of 
this condition as duodenal tumours and intra-abdominal desmoids can develop as extra-
colonic manifestations(Hardy, Meltzer et al. 2000). 
The other well known hereditary colorectal cancer is hereditary non-polyposis colorectal 
cancer (HNPCC), another autosomal dominant condition with incomplete penetrance, also 
known as the Lynch syndrome.  The modified Amsterdam criteria (Table 1) are used to 
provide the diagnosis of Lynch syndrome as the phenotype is not diagnostic as with FAP.  
The original Amsterdam criteria only included colonic cancers but it is now known that 
endometrial and small bowel adenocarcinomas occur as part of this syndrome. 
 
Table 1.1 Modified Amsterdam Criteria(Llor, Pons et al. 2005) 
Not all colorectal cancer families fulfill the Amsterdam Criteria and some other syndromes 
such as Turcot’s, Peutz-Jeghers or juvenile polyposis will present with a higher risk of 
colorectal cancer than normal.  More common are inflammatory bowel disease patients 
(Crohn’s disease and ulcerative colitis) who are at higher risk of developing a malignancy; in 
ulcerative colitis colorectal cancer accounts for a third of deaths(Gyde 1990).  The extent of 
inflammation and disease duration are the main risk factors(Cairns and Scholefield 2002).   
Modified Amsterdam Criteria 
 
 Three or more cases of colorectal cancer in a minimum of two generations 
 
 One affected individual must be a first degree relative of the other two (or more) 
cases 
 
 Colorectal cancer can be replaced by endometrial or small bowel adenocarcinoma 
 
 Familial adenomatous polyposis must be excluded 
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Table 1.2 shows the risk factors associated with colorectal cancer. 
 
 
 
Table 1.2. Factors associated with the varying typed of colorectal cancer.  
 
Sporadic colorectal cancer 
Old age 
Male sex 
Previous cholecystectomy (colonic only)  
Ureterocolic anastomosis 
Nulliparity, late first pregnancy, early menopause 
 
Environmental factors: 
Meat and fat rich diet 
Obesity 
Smoking 
Low fibre, folate and calcium diet 
Sedentary lifestyle 
High alcohol consumption 
Previous irradiation 
Occupational hazards (asbestos exposure) 
 
Personal history of tumours: 
Colorectal polyps 
Previous colorectal cancer 
Previous small bowel, ovarian, breast or endometrial cancer 
 
Familial colorectal cancer 
One affected first-degree relative increases risk 2.3 fold 
Two or more affected first degree relatives increases risk 4.25 fold 
If less <45 years old increases risk 3.9 fold 
Familial history of colorectal adenoma increases risk 2 fold 
 
Colorectal cancer in inflammatory bowel disease 
Ulcerative colitis 
Crohn’s disease 
 
Hereditary colorectal cancer 
Hereditary non-polyposis colorectal cancer (HNPCC) 
Polyposis syndromes:  
familial adenomatous polyposis (FAP), Gardner’s syndrome, Turcot’s syndrome, flat adenoma 
syndrome 
Hamartomatous polyposis syndromes  
Peutz-Jehgers syndrome, Cowden syndrome 
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Dukes’ original 1932 classification of rectal tumours has been extrapolated to include all 
tumours of the colorectum(Dukes 1932). There are three original stages, A, B and C, C is 
further subdivided to represent the level of nodal disease and a more advanced stage D has 
been added on to include cancers that have metastasised.  
Dukes’ A tumour confined to bowel 
Dukes’ B breached bowel wall, no node disease 
Dukes’ C1 Nodes postitive, highest lymph node clear 
Dukes’ C2  Nodes positive, highest lymph node diseased 
Figure 1.1 shows this in diagrammatic form. 
Duke’s A Duke’s B Duke’s C
 
 
 
 
Figure 1.1 
Representation of Dukes’ Staging. The tumour is shown in red, bowel wall in 
pink and the nodes are the white (negative) and black (positive) spherical 
shapes within the yellow fat. 
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Further treatment as well as prognosis is guided by the Dukes’ stage, additionally it is now 
common practice to use the TNM stage for each case.  TNM is the acknowledged method 
used around the world to stage malignant tumours; it is promoted by the UICC 
(International Union Against Cancer) as the gold standard in cancer staging.   TNM staging 
is based on the size of the primary tumour, the T value, the presence or absence of disease in 
the regional lymph nodes, the N value and the presence of distant metastases, the M value. 
Other parameters can be included in the TNM, for example G for grade of tumour and V 
for invasion into vessels although none of these are mandatory for staging. Dukes’ stage can 
be derived from the TNM stage and both are used interchangeably in clinical practice.  Table 
1.3 shows the TNM stages for colorectal cancer. 
 
T stage 
TX 
T0 
T1 
T2 
T3 
T4 
Primary Tumour 
Cannot be assessed 
Carcinoma in situ 
Submucosal invasion 
Muscularis propria invasion 
Through muscularis propria into subserosa 
Tumour invades other organs/structures/visceral peritoneum 
N stage 
NX 
N0 
N1 
N2 
Regional lymph nodes 
No regional lymph node metastases 
1 to 3 nodes positive 
4 or more nodes positive 
M stage 
MX 
M0 
M1 
Distant metastases 
Cannot be assessed 
None 
Present 
 T N M 
Stage I T1, T2 N0 M0 
Stage IIA T3 N0 M0 
Stage IIB T4 N0 M0 
Stage IIIA T1,T2 N1 M0 
Stage IIIB T3,T4 N1 M0 
Stage IIIC Any T N2 M0 
Stage IV Any T Any N M1 
 
Table 1.3 
UICC TNM staging for colorectal cancer. Version 7 2009 
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Pathogenesis: The adenoma carcinoma sequence 
1.1.1.2 Pathogenesis of CRC 
Most colorectal cancers arise as part of the adenoma-carcinoma sequence (Morson, 1978 ) 
There is extensive epidemiological, clinicopathological and genetic evidence for this 
sequence which is shown schematically below. It is thought that normal epithelium, in 
response to environmental factors and dietary carcinogens causes a progression through low 
grade dysplasia to higher grade dysplasia and then eventual carcinoma(Leslie, Carey et al. 
2002). The evidence for the colorectal adenoma carcinoma sequence is convincing; 
oncogenes, tumour suppressor genes and DNA repair genes all contribute to the stepwise 
progression to cancer. The APC tumour suppressor gene, located on chromosome 5q21 is 
mutated early in the sequence and mutation of this gene results in an intracellular 
accumulation of -catenin, a key protein in cell transcription(Rustgi 1993). APC mutations 
are present in a large percentage of colorectal cancers and also in adenomas.  
  
 
 
 
 
 
 
 
 
 
 
Normal colonic epithelium
Early adenoma
Late adenoma
Carcinoma
APC mutations
K-ras mutations
p53 mutations
Figure 1.2  Adenoma-Carcinoma Sequence 
Normal colonic epithelium progresses to adenoma and then cancer through cumulative genetic changes 
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Following on from APC mutations are the Kras and p53 alterations(Kemp, Thirlwell et al. 
2004). K ras mutations occur commonly in adenomas and carcinomas and are part of the 
stepwise progression from normal mucosa through to invasive cancer.  The p53 gene located 
on the long arm of chromosome 17 is lost in many human cancers including colorectal 
cancers; accumulation of p53 protein within the cell may cause the progression of adenoma 
into carcinoma.  Microsatellite instability (MSI) is a further category of abnormality that is 
present in adenomas as well as cancers(Calvert and Frucht 2002). However, what is clear 
from the genetics of colorectal cancer, is that this is a vastly complex area where genetic 
mutations do not occur in isolation and a number of further mechanisms, microsatellite 
instability and mismatch repair proteins, 18q loss and the other alterations in methylation 
status lead to progression to cancer.   Not all adenomas become cancers, those at high risk 
of malignant transformation are the large, sessile or flat polyps, those with a severely 
dysplastic or villous architecture and presence of multiple other polyps(Hardy, Meltzer et al. 
2000).  Polpys are generally considered low risk if they are small, mildly dysplastic and 
pedunculated. The genetics of colorectal cancer must be applicable in the clinical arena and 
this possibility is becoming increasingly likely with time.   
 
Not all adenomas become cancers, those at high risk of malignant transformation are the 
large, sessile or flat adenomas, those with a severely dysplastic or villous architecture and 
presence of multiple other polyps(Hardy, Meltzer et al. 2000).  Adenomas are generally 
considered low risk if they are small, mildly dysplastic and pedunculated. The genetics of 
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colorectal cancer must be applicable in the clinical arena and this possibility is becoming 
increasingly likely.   
1.1.1.3  Management, survival and outcome  
Following staging of the patients, treatment is usually planned by a multidisciplinary team of 
surgeons, radiologists, pathologists and specialist nursing staff and is based on clinical and 
radiological staging.  A CT scan of the liver and lungs excludes or reveals metastases and this 
also provides information on the extent of tumour invasion and lymphadenopathy. For local 
staging in rectal cancer MRI is now preferred owing to its enhanced abililty to distinguish 
tissue planes(Brown and Daniels 2005). The whole colon must be visualised by colonoscopy 
and ideally this is undertaken prior to surgery or very soon after as 5% of patients will have a 
synchronous tumour(Finan, Ritchie et al. 1987). The treatment of colonic cancer is aimed at 
cure through surgical resection with the hemicolectomy forming the basis of treatment.  In 
rectal cancer, Heald’s total mesorectal excision (TME) has reduced morbidity from pelvic 
nerve damage and local recurrence rates as well as improving survival(Heald and Ryall 1986).  
Laparoscopic surgery has been an option in colonic surgery for some time but as yet it has 
not achieved the same degree of acceptance of laparoscopic cholecystectomy. There are a 
number of reasons for this but evidence is now supporting laparoscopic hemicolectomy in 
cancer as being as good a treatment as open surgery and in some series it has been shown to 
better(Lacy, Garcia-Valdecasas et al. 1995). In rectal cancer it has also been shown to be safe 
and effective(Dulucq, Wintringer et al. 2005).  Adjuvant therapies consist of radio or 
chemotherapy or a combination of the two.  In rectal cancer radiotherapy is used 
neoadjuvantly and occasionally postoperatively to prevent local recurrence.  In Dukes’ C 
cancers, adjuvant chemotherapy is given if the patient has a good performance status and 
adequate organ function, the most recent guidelines advocate combination  
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chemotherapy in those that can tolerate it (Scottish Intercollegiate Guidelines Network 
2011).  
 
1.1.2.1 Screening for Colorectal Cancer  
Screening for cancer in the United Kingdom is well established for both cervical cancer and 
breast cancer and these programmes are very successful at detecting early disease and 
preventing cancer deaths(Blanks, Moss et al. 2000). In contrast to this, screening for 
colorectal cancer is in its infancy despite being the second most common cause of cancer 
deaths and there being 35,000 new cases diagnosed in the UK every year (UK 2006). The 
lifetime risk of developing colorectal cancer in Scotland is 5.5% for males and 4.4% for 
females(Executive 2007) Colorectal cancer is highly curable when diagnosed at an early, 
asymptomatic stage but when not detected until later stages it is aggressively fatal 
(Woodman, Prior et al. 1995; Gatta, Faivre et al. 1998).  
 
1.1.2.2 Stool Based Testing  
In Scotland, the government has rolled out a national screening programme using a guaiac 
based Faecal Occult Blood Test (gFOBT) for all males and females registered with a general 
practitioner between 50 and 74 years of age. This commenced in the spring of 2007 and after 
a staged roll out was nationwide by 2009(Steele, McClements et al. 2009).  The programme is 
based on biannual gFOB testing that if positive results in an invitation to attend for a 
colonoscopy. FOBT based screening programmes lead to a reduction in mortality from 
colorectal cancer as demonstrated by population based randomised controlled 
trials(Hewitson, Glasziou et al. 2008) and by analysis of pilot studies in Scotland (Libby, 
Brewster et al.). FOB testing comprises sending a small stool sample to a central testing 
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laboratory where the sample is tested for the presence of haemoglobin. The most widely 
used FOBT works on the principle that guaiac, made from the resin of the Guajacum tree, is 
turned blue by pseudoperoxidases from haemoglobin, in the presence of hydrogen 
peroxide(Anker, Christensen et al. 1974). There are different FOB tests on the market and 
the most commonly used, Haemoccult is a guaiac based test that detects the presence of 
haemoglobin in the stool including animal haemoglobin but also reacts to peroxidases 
unrelated to haemoglobin (Scholefield 2000). The unrehydrated guaiac method has a 
sensitivity of around 50% in a screening context, (Fraser, Matthew et al. 2006). The 
Minnesota trial, one of four large randomised controlled trials that showed a reduction in 
mortality, found that re-hydration raised the sensitivity for cancers from 80.8% to 92.2%, 
with a converse decrease in specificity from 97.7% to 90.4% giving a net reduction in the 
positive predictive value(Mandel, Bond et al. 1993). The mortality reduction in the four large 
trials of FOB screening is shown in Table 1.4. These important trials from Minnesota, 
Nottingham, Denmark and Sweden showed a reduction in colorectal cancer mortality with 
FOB testing ranging from 15% to 33%. Additionally, the Minnesota trial also supported the 
adenoma carcinoma sequence in that it demonstrated a reduction in cancer incidence over 
time, presumably due to therapeutic polypectomy The other trials did not show this 
reduction in incidence presumably because they were associated with a lower positivity and 
thus a lower colonoscopy rate. A Cochrane review in the form of meta-analysis of these 
trials has been carried out showing a reduction of 15% overall from FOB testing.(Hewitson, 
Glasziou et al. 2008) 
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Lead Investigator, date , journal) 
 
Result 
PPV of Haemoccult 
for CRC 
 
Mandel et al(Mandel, Bond et al. 
1993)  
NEJM 1993 
“Minnesota Trial” 
 
33% reduction in CRC 
mortality over 13 years (in 
annual screening) 
21% in biennial 
 
 
2.2% rehydrated 
5.6% unrehydrated 
 
Hardcastle et al(Hardcastle, 
Chamberlain et al. 1996) 
Lancet 1996 
 
 
 
“Nottingham Trial” 
15% reduction in mortality 
over 7.8 years (biennial 
screening) 
 
 
9.9% 1st screen 
11.9% 2ndscreen 
 
Kronborg et al(Kronborg, 
Fenger et al. 1996) 
Lancet 1996 
 
 
 
“Danish trial”  
 
18% reduction in mortality at 
10 years. (biennial screening) 
 
 
17.7% 1st screen 
8.4% 2nd screen 
16.3% 3rd screen 
10.8% 4th screen 
10.2% 5th screen 
Lindholm et al(Lindholm, 
Brevinge et al. 2008) 
British Journal of Surgery 
 
“Swedish trial” 
16% reduction in mortality at 
19 years.  
5.2% overall for cancer 
14% overall for large 
adenomas 
 
 
Table 1.4 Summary of the results of the four large FOB trials that showed a reduction in mortality 
 
1.1.2.3  Faecal Immunochemical Testing 
The other forms of FOB testing are the haemporphyrin tests, such as Haemaquant®, which 
react to porphyrins from haemoglobin and give an estimate of the amount of blood, and the 
immunochemical tests, such as HemeSelect®, which identify only intact human 
haemoglobin Immunochemical faecal occult haemoglobin testing, known as iFOBT or FIT 
testing, offers advantages over the gFOBT. An antibody is used to detect intact globin 
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protein from human haemoglobin, thus permitting no cross reaction with animal derived 
blood protein or with plant peroxidases as can occur with gFOB testing. No dietary 
restriction is necessary when using the FIT test. Additionally, as globin from the upper GI 
tract is readily digested in the gut, blood derived from the upper GI tract either from 
pathological or iatrogenic reasons (eg aspirin therapy) does not cause a positive test. Fraser et 
al have shown that FIT testing in the gFOBT positive population can reduce the number of 
false positive tests and lead to fewer screening colonoscopies in normal patients(Fraser, 
Matthew et al. 2006). They have also demonstrated that the median concentration of 
haemoglobin present in the stool varies in normal patients (13.5ng/ml), high risk 
adenomatous disease (65.6ng/ml) and in cancer (165ng/ml), with wide standard 
deviations(Digby, Fraser et al.).  Immunochemical FOBt testing is more sensitive for cancers 
than for benign neoplasia and is as good at detecting proximal as distal disease(Levi, 2007 ) 
Systematic review and meta-analysis of 19 studies utilising iFOBt (from 1996 to 2013) 
concluded that the test has high overall diagnostic accuracy for CRC detection, with a 
variable degree of success depending on the cutoff value chosen to represent a positive 
result, sensitivity of 79% with a specificity of 94% was found on this analysis (Lee, 2014). 
Reducing the cut off point for a positive can lead to an increase in the detection of 
adenomatous disease but does not show a corresponding increase in detection of cancer. 
There is not as yet a randomised controlled trial using an iFOBt in a screening context.  
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1.1.2.4  Wilson and Junger Criteria 
In order to successfully implement a screening program  the criteria proposed by Wilson and 
Junger must be met (Wilson JM 1968).   
 The condition should be an important health problem 
 There should be an accepted effective treatment for patients with recognised disease 
 Facilities for further diagnosis and treatment should be available 
 There should be a recognisable latent or early symptomatic stage 
 There should be a suitable test or examination 
 The test should be acceptable to the population 
 The natural history of the condition, including development from latent to declared 
disease should be adequately understood 
 There should be an agreed policy on whom to treat as patients 
 The cost of case-finding (including diagnosis and treatment of patients diagnosed) 
should be economically balanced in relation to possible expenditure on medical care 
as a whole 
 Case finding should be a continuous project and not a “once and for all” project. 
 
1.1.2.5  CRC as a candidate for screening 
Colorectal cancer would seem to be an ideal candidate for screening on the basis of these 
criteria. Colorectal cancer is common and is increasing in prevalence in countries that are 
becoming “Westernised”(Sung, Lau et al. 2005). In addition, there is good evidence that 
cancers develop from adenomas(Baba 1997) and that removal of these can reduce cancer 
incidence(Atkin, Edwards et al.; Mandel, Church et al. 2000). Thus screening has the 
potential to reduce cancer incidence provided adenomas can be detected. Treatment of 
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colorectal cancer is well established and curative surgery forms the mainstay of management 
with survival correlating to clinical stage. Surgical management continues to advance with 
new techniques being introduced that may reduce mortality and morbidity even further(Lacy, 
Garcia-Valdecasas et al. 1995),(Dulucq, Wintringer et al. 2005),(Heald and Ryall 1986). 
Tumours that previously would have seemed inoperable are now treatable with adjuvant 
therapies; radiotherapy, chemotherapy and both in combination can be used and there are 
new chemotherapeutic treatments that use less toxic oral drugs rather than the older infusion 
regimes(Weitz, Koch et al.; Kang, Chang et al. 2005).  
Following a positive FOB test facilities are available for further management in the form of a 
colonoscopy and although this is an area of concern for the already overburdened 
endoscopy service in the NHS(Bowles, Leicester et al. 2004) the UK governments 
Departments of Health have given an undertaking that the needs of screen detected 
individuals will be met. Cost is an important consideration and FOBT screening has been 
shown to be both cost-effective(Frazier, Colditz et al. 2000) and sufficiently acceptable to 
the screening population(Homa, Brzosko et al. 2005). Thus colorectal cancer is a convincing 
candidate disease for a screening programme. 
 Determining the screening population, the method of screening and the screening interval is 
slightly less clear cut. There are agreed guidelines for those in high risk groups (familial 
adenomatous polyposis, Lynch syndrome and previous CRC patients) and these are generally 
not included in the discussion for mass population studies(Cairns and Scholefield 2002). 
Only 7% of colorectal cancers occur below the age of 50 so most screening is commenced 
from this age onwards(Imperiale, Wagner et al. 2002). The pilot study in the UK screened 
only those up to the age of 69 but the colorectal cancer screening programme in Scotland 
now includes those up to the age of 74 years as 50% of all colorectal cancers occur in those 
  
24 
 
 
over 70 years old; debate about cost of screening and number of life years saved by 
intervening in this elderly group is ongoing(Walter, Lewis et al. 2005).  
There are a variety of different screening modalities from the high cost, highly invasive 
colonoscopy based screening programme to the low cost non-invasive stool based tests and 
there is debate over the best method. As outlined above it was shown by the Minnesota 
study in 1993 that FOB based screening could reduce mortality from colorectal 
cancer(Mandel, Bond et al. 1993) and this was confirmed when both the Nottingham and 
the Danish studies were published in 1996(Hardcastle, Chamberlain et al. 1996; Kronborg, 
Fenger et al. 1996), and the more recent Swedish study(Lindholm, Brevinge et al. 2008). 
(Cochrane meta-analysis(Hewitson, Glasziou et al. 2008).) In spite of this, many years later 
the debate continues about other modalities demonstrating the difficulties in deciding how 
best to screen.  
 
1.1.3.1  Stool based testing  
There are two main groups of colorectal cancer screening tests, visualisation of the 
colorectum either directly using endoscopes or indirectly using radiological investigations 
and stool based testing, looking for haemoglobin or other markers of neoplasia. The 
majority of studies into colorectal cancer screening have evaluated the use of FOB tests, 
flexible sigmoidoscopy or colonoscopy and the advantages and disadvantages of each are 
addressed in table 1.5.  This table shows that there is relatively little cost and little 
inconvenience in performing an FOB test, including the cost to society and to the patient.  
In contrast a colonoscopy requires at least one and usually two days off work, sedation 
which results in an inability to drive home afterwards, all of which cause a relatively large 
amount of inconvenience.  
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FOB 
 
SIGMOIDOSCOPY 
 
COLONOSCOPY 
CT 
COLONOGRAPHY 
Setting Home Endoscopy suite Endoscopy suite Radiology 
department 
Bowel prep None Minimal Total bowel 
prep 
Total bowel prep 
Fasting None None 24-48 hours 24 hours 
Level of 
training 
required 
None Minimal Highly skilled Highly skilled 
Duration n/a  20 minutes Up to 40 
minutes 
20 minutes 
Cost Cheap moderate expensive Expensive 
Sensitivity for 
cancers 
70% 95% 100% in best 
hands 
“Gold 
Standard” 
 
Day off work No No At least one day  
Morbidity None Low Moderate Low 
Extent of colon 
seen/tested 
Entire 
colorectum 
Up to 60cm Entire 
colorectum 
Entire colorectum 
Further 
investigation 
needed 
Yes if 
positive 
Yes if 
polyp/cancer 
No Yes for tissue 
diagnosis 
Post procedure 
care 
None None Trasnport home 
Supervision 
None 
 
Table 1.5  Comparison of screening modalities. Adapted from Macafee et al(Macafee and 
Scholefield 2003) 
 
Different health care systems and societies accept different levels of cost, sensitivity and 
specificity and risk of complications. Where health care is delivered by the private sector and 
screening is not largely opportunistic there is a preference towards more accurate and more 
expensive forms of screening. The first round of the UK wide pilot showed that of the 
478,250 people invited to take part, 56.8% returned a completed FOB test. The overall rate 
of a positive test result was 1.9% and the rate for detecting cancer was 1.62 per 1000 people 
screened with a positive predictive value of 10.9% for cancer and 35% for adenoma(UK 
Colorectal Cancer Screening Pilot Group 2004). 
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The stage of screen detected cancers was also in contrast to the symptomatic stage 
distribution of cancers, with many more early and potentially curable cancers in the screen 
detected group; 48% of all screen detected cancers were Dukes' stage A, and 1% were 
Dukes’ D at time of diagnosis(UK Colorectal Cancer Screening Pilot Group2004). This is in 
marked contrast to the symptomatic patients and this is illustrated in Figure 1.3. 
 
 
Figure 1.3 Comparison by Dukes’s stage of screen detected versus symptomatic cancers 
 
The 57% return rate was lower in men particularly in the 50 to 55 age group. Those who live 
in deprived areas and in areas where there is a large proportion of people from the Indian 
subcontinent are also less likely to return a sample (Greiner, Engelman et al. 2004).  
 
 
 
 
 
Stage distribution of symptomatic 
cancers
Dukes A
8%
Dukes B
33%
Dukes C
34%
Dukes D
25%
Stage distribution of screen detected 
cancers
Dukes A
48%
Dukes B
25%
Dukes C
26%
Dukes D
1%
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Stool based testing is the initial method of detection in many CRC screening programmes 
and investigation of a positive test can involve either direct visualisation of the colon using 
colonoscopy or sigmoidoscopy or indirect radiological methods such as barium enema 
(usually combined with a sigmoidoscopy) or CT colonography.  
Stool is easily accessible on an almost daily basis, it is transportable and involves no painful 
or cathartic procedure for retrieval and as it journeys through the colon it reflects the surface 
of the entire colorectum. The already established method of screening, the FOBT can be 
performed on mailed in specimens of stool, therefore allowing widespread access to 
screening across all geographical locations. 
However the specificity and sensitivity of the FOBt is far less than the gold standard 
investigation, colonoscopy(Villa, Dugani et al. 1996). The inherent limitations using blood 
for screening is that occult bleeding is intermittent when it occurs from early neoplasms and 
in addition, it commonly occurs in a large number of benign conditions of the 
colorectum(Ahlquist, McGill et al. 1989).  No matter how sensitive the FOB test, there is no 
way of avoiding the fact that on the days of testing the tumour may not be bleeding. To 
allow for this the participants in the Scottish screening programmes are asked to take a 
sample from three separate bowel movements.  If a strong positive result is returned an 
invite to attend for colonoscopy is made, in the event of a weak positive then further stool 
testing is offered in the form of a more specific immunochemical Hema-Screen test, if this is 
negative then the participant is returned to the asymptomatic group to await further 
screening in 2 years and if positive they are invited for colonoscopy.   
Patterns of bleeding from occult colorectal cancers have been studied and are known to be 
highly variable; in particular, the absence of symptoms of colorectal cancer has been shown 
to correlate with a normal faecal haemoglobin measurement. (Doran and Hardcastle 1982; 
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Ahlquist, McGill et al. 1989) In some centres, to avoid the problem of contamination of 
endogenous and animal haemoglobin participants are asked to abstain from red meat and 
NSAID’s prior to testing, though it has been shown that dietary restriction is a barrier to 
screening (Cole and Young 2001). Screening for colorectal cancer has caused controversy 
with many differing opinions on the best way to proceed and despite the evidence, critics of 
FOB based screening advocate caution in rolling out national programmes(Towler, Irwig et 
al. 1998) 
An ideal stool marker would of course be present in high concentrations in early disease, be 
stable in stool and transport media, be easily assayed and be 100% specific and 100% 
sensitive. Ahlquist has proposed a classification system for stool tumour markers based on 
their mechanism of luminal entry; leaked, secreted or exfoliated (Ahlquist and Gilbert 1996).   
 
1.1.3.2 Leaked Markers  
Haemoglobin from blood is the most common leaked marker, other markers that are leaked 
from tumour into stool have been detected and explored as potential screening tests though  
none of these have been adopted as a screening tool. Levels of calprotectin, a leukocyte-
derived protein in the cytosol of neutrophil granulocytes, are increased in the stools of 
colorectal cancer patients(Roseth, Fagerhol et al. 1992). Studies have shown that the levels of 
haemoglobin and of calprotectin are not linear so it is likely not to be leaked into stool in the 
same way as blood(Gilbert, Ahlquist et al. 1996). It is thought that calprotectin gains luminal 
access via interstitial leukocyte migration, which could be a less variable mechanism of entry 
than bleeding(Gilbert, Ahlquist et al. 1996). Testing for calprotectin has been shown to be 
less useful than a sigmoidoscopy as a screening tool and there has not been a large 
comparison of FOB versus calprotectin despite initial hopes that it may replace FOB 
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testing(Roseth, Kristinsson et al. 1993; Hoff, Grotmol et al. 2004) Calprotectin detection is 
facilitated by its stability in stool and reliable estimates can be obtained in samples of only 5 
g. Research in Scandinavia has revealed that 79% of patients with CRC had a raised stool 
calprotectin level but the specificity of this as a marker has not been fully evaluated. It is 
known to be raised in benign inflammatory conditions as well as neoplasia(Kristinsson, 
Armbruster et al. 2001). Current evidence suggests that its higher sensitivity in some series 
compared to the FOB comes with a lower specificity(Tibble, Sigthorsson et al. 2001) which 
in a prospective trial was found to be 63% (Limburg, Devens et al. 2003). 
Lactoferrin is a neutrophil derived glycoprotein that has been measured in a variety of 
disease states.  It was initially described as a marker in inflammatory bowl disease, along with 
other proteins found in stool(Sudo, Igawa et al. 1993; Sugi, Saitoh et al. 1996). Further 
evaluation of this glycoprotein has shown it is elevated in Travel Associated Diarrhoea, 
Clostridium difficile diarrhoea and in paediatric gastrointestinal disease (Scerpella, Okhuysen 
et al. 1994; Steiner, Flores et al. 1997; Ruiz-Pelaez and Mattar 1999).  In addition, a 
prospective pilot study measuring lactoferrin by enzyme linked immunoassay (ELISA) found 
that lactoferrin was as useful as FOB in determining cancer from non-cancer in fresh stool 
samples(Saitoh, Kojima et al. 2000). Recent work has indicated a role for Lactoferrin 
measurement in post-operative inflammatory bowel disease patients to determine 
inflammatory diarrhea pouchitis and also in monitoring response to Infliximab 
therapy(Buderus, Boone et al. 2004; Parsi, Shen et al. 2004). 
Lysozyme is an innate, non-immunologic antibacterial enzyme produced by the Paneth cells 
of the upper intestinal tract. Lysozyme is not normally secreted in the lower intestinal tract 
but it is by colorectal neoplasias and although unstable in stool, it is easily detectable and 
quantifiable(Brouwer and Smekens 1991; Dubrow, Kim et al. 1992).  In addition to being 
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present in the stool of patients with cancers of the colorectum, evidence suggests that this 
marker is present in adenoma tissue, although it has not been demonstrated in the stool 
samples of patients with adenomas(Rubio 2003). 
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1.1.3.3 Secreted Markers 
It may be that substances secreted from the tumour into the lumen of the bowel may 
indicate disease. Mucins found in stool are high-molecular weight epithelial glycoproteins 
with a high content of clustered oligosaccharides. There are two structurally and functionally 
distinct classes of mucins, the secreted gel-forming mucins (MUC2, MUC5AC, MUC5B, and 
MUC6)(Byrd and Bresalier 2004) and the transmembrane mucins (MUC1, MUC3A, 
MUC3B, MUC4, MUC12, MUC17). In addition a number of more difficult to classify 
mucins have been identified (MUC7, MUC8, MUC9, MUC13, MUC15, MUC16) (Limburg, 
Ahlquist et al. 2000).  MUC1 mucin, as detected immunologically, is increased in expression 
in colon cancers, but unfortunately does not discriminate accurately between cancers and 
controls(Limburg, Ahlquist et al. 2000) . Expression of MUC2 secreted gel-forming mucin is 
generally decreased in colorectal adenocarcinoma, but preserved in mucinous carcinomas, a 
distinct subtype of colon cancer associated with microsatellite instability(Ajioka, Allison et al. 
1996; Song, Byrd et al. 2005).  
 
1.1.3.4 Exfoliated Markers 
An estimated 1010 colonocytes per day are continuously shed into the lumen of the bowel 
and eliminated from the body in faecal matter with the entire lining of the colon being 
renewed every 3 or 4 days, offering a continual supply of marker release in contrast to the 
varied nature of bleeding(Sidransky, Tokino et al. 1992). Colonocytes are lost from the 
surface by not only the sloughing caused by the passage of stools but also through apoptosis 
and subsequent engulfment(Eastwood 1977; Eastwood 1992; Eastwood 1995).  One of the 
main features of malignant transformation is the decrease in apoptosis which leads to an 
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increase in the amount of cellular material in the stool samples accordingly colorectal cancer 
patients have been shown to have a significantly higher amount of DNA in their stool 
samples and a larger number of colonocytes(Villa, Dugani et al. 1996). Despite the relatively 
small surface area of a neoplasm in contrast to the rest of the colonic mucosal surface, an 
estimated 24% of recovered DNA in colorectal cancer patients is tumour DNA(Ahlquist, 
Harrington et al. 2000). In addition to loss of apoptosis there is increased proliferation of 
cells and less adhesiveness between cells. Due to the large amount of cellular debris within 
faecal samples and our ability to perform polymerase chain reactions to amplify areas of 
DNA, genetic tests are increasingly being explored as potential stool based tests for 
colorectal cancer and K-ras mutations were identified as early as 1992 in stool samples 
(Sidransky, Tokino et al. 1992). DNA is stable within stool, and fragments of colonocytes are 
easily assayed. However, whole colonocytes are not stable in stool and isolating them can be 
challenging(Davies, Freeman et al. 2002). The amount of non-human DNA in stools may 
also be a confounding factor, and distal tumours seem easier to detect than proximal 
tumours, perhaps because the environment in the right colon is more hostile to DNA.  
The genetic mutations associated with colorectal cancer are heterogeneous and a panel of 
DNA changes is more useful than one single abnormality. Multi target DNA markers are by 
far the most promising, covering many known genetic changes in colon cancer, but they are 
costly. Alquist used a panel that gave a sensitivity for cancer of 91% and 82% for adenomas 
with a specificity of 93%. Excluding K-ras from the panel, sensitivities for cancer were 
unchanged but decreased slightly for adenomas to 73%, whilst specificity increased to 100% 
for cancer (Ahlquist, Skoletsky et al. 2000).  
DNA tests are very cancer specific and so false positives are not returned from patients with 
benign disease, unlike FOBT. The tests that have been described in the literature are highly 
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sensitive and specific and like the FOB specimens can be colleccted at home and do not 
require bowel preparation.  However, considerable further work is required to decide the 
most appropriate combination. In addition, stool DNA testing may answer more questions 
than just the presence or absence of colorectal cancer and other cancers more proximal in 
the gastrointestinal tract can also be detected using DNA based stool tests(Ahlquist DA 
2000).   
 
1.1.4.1 Endoscopic Screening 
Endoscopic methods of screening have been proposed using either sigmoidoscopy or 
colonoscopy; colonoscopy is widely regarded as an impractical method in the UK due to 
cost, the potential complications (including death) and lack of trained staff to perform the 
huge number of screening tests that would need to be done. In the United States, where the 
private sector and insurance companies shoulder the cost, there is a growing body of support 
that promotes colonoscopy as the primary means of screening and it is recommended by the 
American College of Gastroenterologists as the preferred mode of screening.(Bhattacharya 
and Sack 1996; Podolsky 2000) (Rex, Johnson et al. 2000) Many of the studies evaluating 
endoscopic methods of screening are case control studies where the end point is incidence 
and not a reduction in mortality(Selby, Friedman et al. 1992; Winawer, Flehinger et al. 1993; 
Segnan, Senore et al. 2005).  
 
1.1.4.2 Flexible sigmoidoscopy 
Flexible sigmoidoscopy (FS) has been proposed as a screening tool as most cancers and 
polyps occur in the area of the colon that the flexible sigmoidoscope can reach (60cm from 
anal margin)(Atkin, Cuzick et al. 1993). The finding of a cancer at sigmoidoscopy or of a 
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“high risk” polyp can be used to trigger a completion colonoscopy to visualise the whole 
colon to screen for a synchronous pathology. The benefits of flexible sigmoidoscopy over 
colonoscopy are less training time needed for the endoscopist, less time off work for the 
patient, less cost and less bowel preparation and a theoretical corresponding higher uptake. 
The baseline findings of a UK trial which sub selected only motivated patients to be 
randomised reported an uptake of 71%. Of those screened, 72.3% had no abnormality and 
of the abnormal group,  4.7% had high risk lesions and 0.3% had cancer(UK Flexible 
Sigmoidoscopy Screening Trial Investigators, 2002).  
The study published in 2010 by Atkin et al involved 14 UK centres and included 170 432 
patients from a normal screening population, between the ages of 55 and 64 years.  They 
were offered a once-only flexible sigmoidoscopy (57 237 participants assigned to FS, 71% 
uptake). In per protocol analysis, colorectal cancer incidence was decreased by 33% overall, 
by 50% for distal colon and rectal cancers and mortality was reduced by 43%. These results 
are impressive but the incidence of right sided cancers was not decreased. 
The likelihood of having no distal lesion and a synchronous caecal or other right sided 
cancer was thought to be rare, but a study published in 2000 showed that by failing to fully 
investigate the colon with colonoscopy and giving those with no distal polyps on 
sigmoidoscopy a clean bill of health will result in half the cases of advanced proximal 
neoplasia being missed(Imperiale, Wagner et al. 2000).  However, other studies have not 
supported this finding and a more recent study looked at polyps in the distal colon detected 
during colonoscopy and assessed risk depending on polyp type. Advanced neoplasia 
occurred in the right side in just 2% of patients with no polyps, 2% with distal hyperplastic 
polyps and 4% of those with adenomas. Based on these findings the authors suggested that 
the discovery of hyperplastic polyps at sigmoidoscopy does not necessitate further 
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colonoscopy(Lin, Schembre et al. 2005). A meta analysis of this topic, by Dave et al 
concluded that in an asymptomatic person, a distal hyperplastic polyp is associated with a 
21% to 25% risk for any proximal neoplasia and a 4% to 5% risk of advanced proximal 
neoplasia(Dave, Hui et al. 2003).  Meta analysis of studies using the screening population in 
America has shown that distal adenomatous polyps, regardless of size, are associated with an 
increased prevalence of synchronous proximal neoplasia with an odds ratio of 2.4.(Lewis, Ng 
et al. 2003).  
In recent years there has been a proximal migration in cancer locations and now caecal 
cancers and ascending colon cancers account for an increasingly large proportion of all 
tumours. (Levi, Randimbison et al. 1993).  The biology of right sided cancers may be 
different to those that occur on the left and in the rectum and certainly right sided cancers 
are likely to occur in older patients(Slater, Papatestas et al. 1982).  FS has been unfavourably 
compared to performing a mammogram on just one breast and may not be acceptable to the 
population on the grounds that it is only investigating the highest risk area of the colon and 
is ignoring what may be just around the corner(2002; Macafee and Scholefield 2003). Despite 
these concerns, flexible sigmoidoscopy is being rolled out in England starting from March 
2013 for men and women aged 55 to 60 years, before FOBt screening starts. Another option 
is to use flexible sigmoidoscopy in direct combination with FOBt. Several studies have 
detected more pathology using FOBt with FS as than from using the FOB alone. However, 
the evidence points to poor compliance in the arms randomized to FS and FOB instead of 
just FOB(Berry, Clarke et al. 1997; Rasmussen, Kronborg et al. 1999).  
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1.1.4.3 Colonoscopy 
Although colonoscopy is unlikely to be adopted by publicly funded health care systems, it is 
advocated by the American Society of Gastroenerology as the preferred method of 
screening; a colonoscopy every ten years for those over 50 is recommended(Walsh and 
Terdiman 2003) 
Currently there are no completed randomized controlled trials to support its use in this 
context but there are a large number of case control studies that have shown a decrease in 
incidence of colorectal cancer following a colonoscopy. The protective effect of having a 
normal colonoscopy is thought to last ten years although this is based on evidence derived 
from studies involving flexible sigmoidoscopy(Selby, Friedman et al. 1992). A cancer 
incidence of less than one percent over 5 years following a normal colonoscopy has been 
shown by smaller case control studies, when individuals are in low risk groups and 
asymptomatic.(Rex 1996; Zauber 1997) 
The risk from a screening colonoscopy also must be considered; in expert hands there is 
little risk of colonic perforation occurring but there is a morbidity of 0.3% associated with 
the procedure including a risk of death (Walsh and Terdiman 2003) Cost is one of the most 
prohibitive factors, it has been estimated that a colonoscopy costs £3000 per life year saved 
in contrast to just £1000 for an FOBT and £1500 for a flexible sigmoidoscopy(Scholefield 
2000) 
 
1.1.4.4. CT Colonography  
This relatively novel radiological technique allows excellent visualisation of the adequately 
prepared colon using multi-slice helical CT scanning which can be used to create a 3-
Dimensional image or “virtual colonoscopy”.  As in colonoscopy, the patient is again 
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required to take the bowel cleansing preparations necessary to purge all faecal material from 
the colon. The colon is inflated with gas and then the patient is scanned in the supine and 
prone positions, the data being displayed as a 2 or 3-D image.  
The advantages of this technique are that the patient does not have to undergo a 
colonoscopy unless there is pathology that requires treatment or further investigation. It also 
has been suggested that patients prefer some degree of choice as they may not want a small 
polyp removed and prefer to be followed up over time by repeat CTC as the fate of such 
small polyps may not involve malignant progression (Eide 1991). In addition there are 
potential social benefits; there is no sedation required so that the patient can drive 
themselves home from the hospital and they do not require supervision afterwards.  
There are disadvantages, however. There is no means of performing any therapeutic 
procedure or of obtaining tissue for diagnosis, discovery of pathology necessitates further 
colonoscopy with more bowel preparation and time off work and false positives are 
common as diverticular disease, prominent ileocaecal valves and thick haustral folds can all 
mimic polyps or cancers. Other problems, particularly common in the elderly screening 
population, are related to metal artefacts (such as hip prostheses) causing streaking on the 
CT scan image. In addition, there is the problem of delivering very high doses of radiation 
over a period of time which carries the albeit small, theoretical risk of causing 
cancer(Brenner and Georgsson 2005). 
The sensitivity of CTC has been found to be highly variable in one study. Comparing the 
findings of CTC by three different highly trained radiologists with colonoscopy immediately 
afterwards showed that CTC interpretation detected an average of 63% (variability of 32% 
to 74%) of the 59 polyps greater than 1 cm seen at colonoscopy(Johnson, Harmsen et al. 
2003). The low pick up rate in general as well as the high interobserver variability is 
  
38 
 
 
concerning.  CTC is also not useful for identifying flat adenomas and small adenomas with 
sensitivity as low as 13% in one series(Fidler, Johnson et al. 2002).  Even with increasingly 
detailed 3D reconstruction of the segments of interest it is still easy to miss a premalignant 
lesion less than 1cm, though some would argue that it is not necessary to detect adenomas 
less than this size(Atkin 2003).   
Ethical problems and treatment dilemmas are created when CT scans detect other 
pathologies that are not related to colorectal cancer screening.  The screening population are 
high risk for other pathologies and two studies in the United States, from the same hospital, 
have a large number of incidental findings. Hara et al in the Mayo clinic found 151 
pathologies in 109 of their 264 patients that were not related to their colon. 23% of these 
were “highly important” findings which resulted in further investigation (e.g. renal mass, 
abdominal aortic aneurysm, etc)(Hara, Johnson et al. 2000). A different group in the same 
department of the Mayo clinic published further results just three years later; they found in a 
larger sample size they had a similar pick up of a huge number of findings, but that just 10% 
of them were of high clinical importance(Gluecker, Johnson et al. 2003).    
Where CT colonography may be useful is in screening patients when it is not possible to 
perform a colonoscopy due to frailty or if colonoscopy would require a general anaesthetic. 
It is useful to diagnose disease even when the intention is not curative as it can guide 
treatment and allow a prognosis to be given. Current practice is to perform a Barium enema 
if it is not possible to complete a colonoscopy but this technique does not visualise the 
sigmoid colon well. There is research ongoing into improving CTC using methods such as 
electronically subtracting stool from the images by giving the patient faecal tagging 
preparations, low residue diets and novel software packages. If the technique can be further 
evolved to remove the need for bowel preparation it may well be that CT colonography will 
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have a role in screening but it is unlikely to be applicable in mass population 
studies(Nicholson, Barro et al. 2005). MRI scanning would be ideal as there is no radiation 
involved and this is subject to ongoing evaluation. 
 
1.1.5 Serum Markers 
It can be argued that there is little to be gained from developing tests that detect advanced 
cancers, what is urgently needed is a biomarker for early disease. The most established 
marker in colorectal cancer is CEA (carcinoembryonic antigen) and this used in follow-up 
but not in the diagnosis of primary, curable disease(McArdle 2000).  CEA is a high molecular 
weight glycoprotein that is thought to play a role in cell adhesion and apoptosis and it has 
been shown that injection of CEA into mice enhances metastases(Hammarstrom 1999).  
Various studies have looked at CEA sensitivities for each Dukes’ stage, and one used CEA 
in combination with CA 242(Kim, Fernandes et al. 2003) as illustrated in Table 2.  
Table 1.6 Sensitivity of serum biomarker for each Dukes stage comparing CEA alone, CA242 and the two 
markers combined. 
 
For CEA to be useful in screening it would need to detect early disease which it does not; 
CEA detection in a normal population would result in a failure to detect almost half of the 
cancers(Duffy, van Dalen et al. 2003). CEA is neither sensitive nor specific for colorectal 
cancer with estimates of approximately 87% specificity and 40% sensitivity(Fletcher 1986). 
Stage CEA alone CA 242 alone CEA and CA 242 
Dukes A 27.8% 11.1% 33.3% 
Dukes B 32.4% 16.2% 48.6% 
Dukes C 32.1% 30.8% 40.7% 
Dukes D 66.7% 50% 72.5% 
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Serum CA 19-9(Morita, Nomura et al. 2004) has been widely investigated as a tumour 
marker in gastrointestinal malignancy and although it is commonly used in the diagnosis of 
pancreatic adenocarcinoma it has been evaluated in colorectal cancer.(Nakagoe, Sawai et al. 
2003; Fuszek, Lakatos et al. 2004; Morita, Nomura et al. 2004; Chen, Yang et al. 2005)  
However, it again is not of use in diagnosis of early cancer although it may have a role in 
predicting poor outcome in colorectal cancer(Lindmark, Bergstrom et al. 1995) . 
Another novel protein found to be present in colorectal tumours and also in the serum of 
colorectal cancer patients at significantly higher levels than in controls, is Nicotinamide N-
Methyltrasferase, normally produced in the liver (Roessler, Rollinger et al. 2005).  This has 
been shown to be more useful than CEA at detecting cancer from normal controls.  The 
drawback of this marker is that it is produced in large quantities in liver disease and so may 
generate false positive results in this population.  Further evaluation is needed for this to 
become acceptable as a clinical marker.  Other tumour derived serum markers have been 
detected using proteomics to first identify proteins alpha-defensins 1 to 3 in solid tumour 
and an ELISA test then developed to detect the proteins of interest. This ELISA was then 
used on the serum of the patients who had the original tumour and gave a sensitivity of 68% 
and specificity of 100% for cancer(Melle, Ernst et al. 2005).   
There are a variety of other serum markers, CA 72-4, hCG (Louhimo, Alfthan et al. 2004), 
calcium (Fuszek, Lakatos et al. 2004) and ferritin (Griffiths and Schapira 1991; Scholefield, 
Robinson et al. 1998) as well as other more novel and unusual proteins that have been 
evaluated and current recommendations are that they  are not of use in screening(Duffy, van 
Dalen et al. 2003).  Where they may be useful, is in predicting response to therapy and 
perhaps in prognosis (Louhimo, Alfthan et al. 2004). 
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More recently, testing for circulating methylated DNA has attracted interest. As an example 
the Septin 9 test is now commercially available but it is associated with a sensitivity of 74% 
and a specificity of 90%(Warren, 2011). 
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1.1.6 Conclusions 
Screening using FOB testing and colonoscopy is now established practice in many countries. 
There is no doubt that the FOBT is an imperfect test and although the reduction in 
mortality for screening with this method remains impressive, it is associated with appreciable 
false positive and interval cancer rates. Any screening test that achieves the twin demands of 
high sensitivity and high specificity as well as being cost effective and acceptable will be 
enthusiastically welcomed but as yet this remains elusive. The current goal of the screening 
programme is to reduce  mortality from colorectal cancer and to eventually lead to fewer 
numbers of people presenting with advanced cancers. Population screening reduces the risk 
of colorectal cancer death occurring for a small number of individuals within large 
asymptomatic populations. Good uptake is crucial in order to achieve a reduction in deaths; 
the key to this is education for the public regarding colorectal cancer screening and, in 
contrast to other screening programmes which only identify malignant disease, there is the 
benefit of polypectomy in reducing cancer incidence.  
Although the main aim of the screening programme is to reduce the mortality from 
colorectal cancer through early detection, any test that can reliably identify adenomatous 
polyps has the potential to reduce disease incidence.  Efforts to find a better test have 
focussed largely on refining the FOBT, particularly by means of immunological technology 
and on the implementation of endoscopy based screening. However, increasingly 
sophisticated methods for detecting potential markers has opened up new fields and 
proteomics represents a promising avenue in this respect. 
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Chapter 1 
Section 2 
Clinical Applications of SELDI-TOF Proteomics  
1.2.1 Novel Technologies 
Novel proteomic technologies have the potential to advance our understanding of diseases, 
aid in the development of new strategies in therapeutics, permit scrutiny of organ, cell and 
intra-cellular protein expression and facilitate the search for novel biomarkers for the early 
detection of disease. Cancer is one of the leading causes of death in the developed world but 
although early diagnosis and intervention is associated with improved outcomes in cancer 
survival, simple diagnostic tests with high levels of sensitivity and specificity are 
lacking(Mayor 1998). Many tumour markers in current use are proteins which are either 
present or have their presence in the blood altered in the disease state; prostate specific 
antigen (PSA) is probably the most widely used but its limitations are well known(Carter and 
Isaacs 2004). From the earliest days of tumour markers, attention has been on the 
identification of informative proteins in easily accessible body fluids and the science of 
proteomics has opened up a new range of opportunities in this area(Rosenfeld 1987). 
Proteomics can be defined as the large-scale analysis of the expressed protein complement 
of the genome(Feldman, Espina et al. 2004).  The word proteome was first coined in 1994 
and the human blood proteome is exceptionally complex, containing many different 
proteins, the most abundant being albumin. These proteins exist in various forms and sizes, 
existing in various states including precursors, mature forms, degradation products and 
differing degrees of post-translational modifications. Immunoglobulins, peptide and protein 
hormones, cytokines and other local mediators, tissue leakage products (creatinine kinase, 
cardiac troponins) as well as foreign proteins and aberrant secretions give rise to tens of 
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thousands of different proteins(Anderson 1995),(Anderson and Anderson 2002).  With such 
a rich source of information easily available for sampling, interest has focused on searching 
for serum proteins that can offer simple, cheap, non-invasive tests for cancer and the 
coupling of bioinformatics with the new, high throughput mass spectrometry based tests has 
allowed rapid expansion in the field of biomarker discovery(Celis and Gromov 2003).  The 
early detection of cancer, the monitoring of cancer treatment and individualization of 
therapy may all benefit from the discovery of as yet unknown biomarkers. Separation and 
identification of proteins is classically facilitated by two-dimensional polyacrylamide gel 
electrophoresis (2D PAGE)(Rabilloud 2002).  The proteins of interest are made soluble and 
are then separated on the basis of charge over one dimension and molecular mass over the 
second.  A current applied across the soluble proteins on a polyacrylamide gel strip allows 
the first stage of separation to occur and following further separation by mass, proteins can 
be visualized by staining with various techniques, such as coomassie blue and silver. Proteins 
of interest can be excised from the gels and subjected to sensitive and accurate mass 
spectrometric analysis and the mass spectral data is then used to interrogate specialized 
computer software protein identification databases (such as ProFound and Mascot)(Zhang 
and Chait 2000). These online data bases have allowed comparison of data and serve as a 
reference for investigators.  
Mass spectrometers consist of an ion source, a mass analyzer that measures the mass to 
charge ratio and a detector to pick up the number of ions of each mass but peptides and 
proteins are difficult to measure by means of the usual mass spectrometry methods as they 
are often destroyed by the ionization process.(Aebersold and Mann 2003)  2D gel 
electrophoresis combined with mass spectrometry has limitations; in particular, it cannot 
accurately measure small differences in concentration and the traditional method of 2D 
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PAGE, despite some recent technical advances, is time consuming and not amenable to 
processing large numbers of samples(Rodland 2004). The results of tissue analysis by 2D-
PAGE are greatly enhanced by laser capture microdissection (LCM) as this improves 
specificity and despite the disadvantages mentioned above, it remains a good means of 
detection of biomarkers(Banks, Dunn et al. 1999). Matrix-assisted laser/desorption 
ionisation time-of-flight mass spectrometry (MALDI-TOF MS) offers a more sensitive 
means of identifying small volumes of proteins and this rapidly became an accepted 
technology following its discovery.  MALDI can determine the mass of a protein or peptide 
with a high degree of accuracy and it was quickly recognized that the masses of peptides 
generated from a pure fragmented protein with an enzyme of known size, such as 
trypsinogen, could uniquely identify a protein(Patterson 2003).   
 
1.2.2.1 SELDI-TOF MS 
Surface enhanced laser desorption/ionisation time of flight mass spectrometry (SELDI-TOF 
MS) offers a similar means of analyzing biological mixtures, the main difference between 
MALDI and SELDI being that in MALDI-TOF the surface or beads are passive probes and 
do not form part of the reaction whereas in SELDI-TOF, proteins from a biological sample 
are immobilized on one of a variety of chip surfaces, all with different binding specificities.  
A few microlitres of sample are bound onto the chemically treated surface of the chip by 
incubating the sample over a short time. The surfaces of the arrays have different specific 
properties; for example, the two ionic protein chip array surfaces consist of one strong 
cationic surface that binds proteins and peptides with a negative charge and the ionic surface 
which binds positively charged molecules. The arrays are 10mm wide by 80mm in length and 
have either 8 or 16 spot surfaces.  
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Figure 1.4 
A Ciphergen ProteinChip showing the 8 spot array. Sample is bound onto the active chip surface 
 
Washing the chip thoroughly after binding removes any impurities and unbound proteins. A 
matrix, such as -cyano-4-hydroxycinnaminic acid (CHCA) which generates matrix ions less 
than 800 Daltons is then added which acts as an energy absorbing molecule. CHCA is 
particularly useful when peptides are being sought instead of heavier proteins as the matrix 
signal on the profile is at a low mass to charge ratio so that the signals from the peptides are 
not masked by the matrix noise. Sinnapinic acid, another matrix, generates higher mass to 
charge ratio ions, typically less then 2000 Daltons and is generally used in protein analysis.  
The matrix is applied to the chip surface in a saturated solution of 10% acetonitrile and 1% 
trifluoroacetic acid and as it dries onto the surface of the chip the proteins crystallize. The 
chip is then placed in a vacuum and a laser is directed on to the surface causing the desorbed 
proteins to be launched as charged ions by the addition of (usually one) proton. The vacuum 
chamber has an acceleration region and a free flight region, known as the drift tube and ions 
leaving the source are accelerated to the same energy through the drift tube by a voltage of 
20kV applied across the surface of the chip. The time-of-flight (TOF) for each ion is 
analyzed to determine the mass to charge ratio (m/z), and as different masses have different 
velocities they arrive at the detector at different times.  This is shown in Figure 1.5. 
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Figure 1.5 
The chip is placed in the machine and a vacuum is created, a charge is applied across the surface and then a 
laser shone on the chip to lift the bound proteins. The particles then fly across the chamber and are detected at 
the other end of the tube where the time of flight is recorded. 
 
The computer program attached to the analyzer then measures the time of flight and gives a 
mass to charge ratio. The equation shown shows how the mass charge ration is calculated 
from the time of flight, as speed equals distance over time. 
E= ½ mv2 
 
m/z =  2V       where  v = x = x1+ x2 
                         x2                                  t      t1+ t2 
 
m/z = 2V     .t2 
                         x2 
 
 
Assuming      2V     is constant   V=acceleration voltage 
                              x2     v= average final velocity 
   
 
m/z = K . t2 
 
Equation for calculating time of flight 
 
The accuracy of the machine is aided by regular calibration using samples of a known 
molecular weight and this can be done by adding known protein standards to the chip 
containing the sample (internal calibration) or running the standards through the machine on 
a separate chip (external calibration).   
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Figure 1.6 
A typical SELDI-TOF profile showing peaks at mass/charge ratios which correspond to size in Daltons. The y 
axis shows the amount detected at the detector plate relative to other particles. Results can be viewed as a peak 
profile or as a gel view as shown in the figure above.  
 
A typical SELDI-TOF proteomic profile will have anywhere up to 15 500 data 
points(Petricoin and Liotta 2004); these large amounts of data require dedicated proteomic 
bioinformatic data mining tools, which utilize two different methods of analysis.  In the first 
system, the outcome is known ahead of time (so called “supervised” systems) and this type 
of system requires “training” by teaching the system which profiles represent diseased and 
which represent healthy states.   
 
Proteomic patterns are analyzed by comparison to the training data and are given a score as 
to how much they resemble the original training data spectra. As the system looks at more 
and more spectra it can eventually learn to identify a new phenotype even if it has not been 
trained to see it beforehand.  In the second “unsupervised” system, data are clustered into 
groups without previously being “taught” which are diseased.  These systems are also 
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vigilant i.e. they learn and adapt as they analyze more data and there is a variety of pattern 
recognition tools that have been used for mining mass spectrometry data(Adam, Qu et al. 
2002; Conrads, Zhou et al. 2003).   
 
Sample fractionation, dividing complex biological mixtures into aliquots according to 
specific properties, can be used to improve the detection of low abundance proteins. SELDI 
accounts for the inherent variability of protein properties e.g. extent of hydrophobia, 
isoelectric point, by the different conditions of each surface and different spectra are 
generated from the same sample on different surfaces.  The analysis of smaller abundance 
proteins, the subproteome, is aided by the removal of higher abundance proteins, e.g. 
albumin in serum samples.  One of the main shortcomings of SELDI is that the relationship 
between the amount of substance present and the corresponding signal intensity is complex 
and not fully understood.   
 
1.2.3.1 Proteomics in Diagnosis 
Despite advances in understanding of the molecular basis of cancer the associated changes in 
protein profiles have been difficult to study until the advent of novel proteomic 
technologies. The dynamic nature of proteins, particularly in abnormal states, makes 
capturing changes particularly challenging but SELDI-TOF MS technology meets the 
challenges of both high sensitivity and high throughput. There has been much interest in 
proteomics as a platform for developing diagnostic tests, with particular reference to it as a 
screening tool in a wide variety of cancer types and the most promising recent studies have 
employed SELDI-TOF(Baak, Path et al. 2003; Rogers, Clarke et al. 2003; Gretzer, Chan et 
al. 2004; Wong, Cheung et al. 2004; Zhao, Gao et al. 2004).    
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1.2.3.2 Ovarian Cancer 
In 2002 Pertricoin et al reported a SELDI-TOF generated proteomic pattern that had a 
100% sensitivity and 95% specificity for ovarian cancer serum detection(Petricoin, Ardekani 
et al. 2002).  In this study, 50 cancer spectra were compared with 50 benign disease spectra 
and using an algorithm of the key low molecular weight marker proteins, a masked set of 
serum samples were used to identify cancer from non-cancer.  The controls used were well 
matched and had other benign gynaecological disease or were “normal”.   Understandably 
this paper generated a lot of interest and enthusiasm about SELDI-TOF MS (the authors 
won immediate praise from the press and the United States Congress passed a resolution to 
intensify this area of research(Congress 2002)) but it came under criticism from the mass 
spectrometrists and the scientific community (Sorace and Zhan 2003; Baggerly, Morris et al. 
2004).  The data made public by Pertricoin’s group was reanalyzed and a series of problems 
centered on the baseline signal. This signal is highly variable from day to day and between 
machines and is usually due to matrix noise and to background electrical interference.   
Matrix noise is maximal below 2000 Daltons and the company that manufactures the 
technology (Ciphergen Biosystems, Fremont, CA) advocate ignoring protein peaks below 
this value. The work by Petricoin et al used peaks in this region to differentiate between the 
study groups and hence the interpretation of the results was based on unreliable data.  
 
1.2.3.3 Head and Neck Cancer 
In head and neck cancer SELDI-TOF proteomic analysis achieved 68% sensitivity and 73% 
specificity at detecting cancer from non-cancer in a study of 56 patients and 52 controls 
recruited from companions of the patients. Plasma profiles showed good reproducibility of 
the spectra on different days and on different chips opening up possibilities in this cancer 
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type.  However, all the patients had quite advanced disease (stage III or IV) due to them 
being recruited from another study, so that the utility of this for screening as a screening test 
is not clear. (Soltys 2004).  
1.2.3.4 Prostate Cancer 
Several groups have looked at prostate cancer tissue which unsurprisingly, yields different 
spectra to normal healthy prostate samples (Zheng, Xu et al. 2003). Serum studies have been 
carried out aiming to detect biomarkers that could replace prostate specific antigen (PSA) 
and many different protein peaks have been identified using SELDI-TOF MS (Table 
1(Hlavaty 2001; Adam, Qu et al. 2002; Petricoin, Ornstein et al. 2002; Qu, Adam et al. 2002; 
Ornstein, Rayford et al. 2004)). One of these groups went on to identify their biomarker in a 
subsequent publication, and when comparing cancer of the prostate to benign prostate 
disease, found their serum marker (which  gave them 96% sensitivity) to be a vitamin D 
binding protein(Hlavaty, Partin et al. 2003).  It is surprising that despite using the same chip 
surface, only two protein peaks were found in more than one study, these have been 
highlighted in bold.  The groups conclude that the proteins that they identified are produced 
by the diseased prostate gland much the same way as PSA is leaked into the circulation by 
the prostatic columnar cells, but critics suggest that the molecules that are detected are 
related to the “epiphenomena” of cancer i.e. malnutrition, inflammatory cytokines, infection 
or cachexia (Diamandis 2003).  What the differences make clear is that the methodology of 
sample handling and of analysis must be of extreme importance.  The molecular mass of 
PSA is 27 755 Da but it was not detected by the SELDI-TOF MS analysis in these groups’ 
experiments (Belanger, van Halbeek et al. 1995).  The proteins detected were in the lower 
molecular range and this calls into question the sensitivity of SELDI-TOF.  Of particular 
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concern is that only those proteins which are abundant in the sample bind to the chip 
surface.  PSA provides the perfect example of this as it is found at a concentration of 
between 4 and 20g/L in the serum of prostate cancer patients whereas the overall total 
protein content is 3 to 5g/L.  
1.2.3.5 Pancreatic Cancer 
In one study patients  undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma 
had preoperative blood taken for SELDI analysis(Koopmann, Zhang et al. 2004).  The 
control group consisted of patients with non-malignant disease of the pancreas (cysts, acute 
pancreatitis, chronic pancreatitis) and a subset of healthy people with no pancreatic disease. 
Four peaks were found that were significantly better than CA19-9, the currently used serum 
biomarker for pancreatic adenocarcinoma, at discriminating cancer from healthy controls 
and in the acute and chronic pancreatitis group they found different peaks that again were 
significantly better than CA 19-9.  This study was particularly promising as the cancer group 
studied consisted of patients with small surgically resectable tumours who are potentially 
curable.  
 
1.2.3.6 Breast Cancer 
In breast cancer, mammography screening is well established but there are drawbacks to this 
modality as it delivers a dose of radiation and detects tumours only when they are large 
enough to cause an alteration in the mammogram image. Serum tumour markers for breast 
cancer (e.g. CA 15-3) are therefore being investigated although they lack the sensitivity and 
specificity required to be widely used in detecting early disease in populations(Ghnassia, 
Rodier et al. 2001). SELDI-TOF analysis of serum from 169 women, comparing cancer to 
benign breast disease has successfully discriminated cancer from non-cancer by using a panel 
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of three biomarkers(Li, Zhang et al. 2002).   Two of these markers were up regulated and 
one was down regulated in patients with cancer and these were found to have a sensitivity of 
93% and a specificity of 95% in discriminating between the cancer and normal or benign 
disease. No correlation was seen with amount of biomarker and tumour size or with lymph 
node status.  Other, non-SELDI proteomic studies using MALDI and 2D-PAGE have 
found circulating serum proteins common to breast cancer patients which can discriminate 
between healthy and cancer patients serum with a 100% sensitivity and a 97% specificity(Rui, 
Jian-Guo et al. 2003).   
 
1.2.3.7 Colorectal Cancer 
Novel screening methods for colorectal cancer are required as the currently employed FOB 
tests lack sensitivity and specificity depending on the analytical sensitivity for haemoglobin 
and endoscopy is associated with poor uptake and is therefore of questionable value for 
population screening (Dachman and Yoshida 2003; Hardt, Toepler et al. 2003; Levin, 
Brooks et al. 2003; Whynes 2004).  
 
A group in China searching for an identifiable colorectal cancer proteomic fingerprint in 
serum recently published their results(Zhao, Gao et al. 2004).  Using the immobilized metal 
affinity capture chip (IMAC3) they analyzed serum from 73 cancer patients, 31 healthy 
patients and 16 cases of benign colorectal disease.  They identified nine different markers 
and achieved impressive results with a sensitivity of 95.89% and specificity of 97.87%.  The 
criticisms of this study are mainly that the control group included patients with adenomas 
and familial adenomatous polyposis.  Another group, again in China, published results from 
a similar experiment that gave comparable results in colorectal cancer identification(Yu, 
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Chen et al. 2004); this group used a different chip surface to IMAC3(Zheng 2004) and a 
comparison of the two groups’ results reveals no biomarker proteins in common, 
presumably related to different methodologies employing different chip surfaces.  The key to 
accepting these biomarkers as diagnostic tests for colorectal cancer will rely on large 
numbers of patients and reproducible results corroborating the evidence from individual 
laboratories.   
 
1.2.4.1 Other Screening Approaches 
1.2.4.2 Cell Lines 
Shiwa et al(Shiwa, Nishimura et al. 2003) used cancer cell lysates from 39 different cell lines 
and analyzed them onth five different chip surfaces.  They identified a marker protein of 
12kDa, prothymosin-at was detected in high concentrations in colorectal cancer cells but 
not in normal colonic epithelium.  Despite the small number of samples, four normal and 
four colorectal cancer, the cell extract profiles were striking and prothymosin-was not 
identified in any other cancer cell line.  Prothymosin-is an acidic nuclear protein found in 
cells as opposed to serum so any implication as to its use as a screening biomarker is limited. 
However, in patients with metastatic adenocarcinoma of unknown primary there could be a 
role to differentiate one type of tumor from another in order to guide therapy.  Villin , a 
microfilament associated protein that binds actin has been identified by proteomic profiling 
as being important in identifying colorectal from ovarian cancer in cell line 
studies.(Nishizuka, Chen et al. 2003)  
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1.2.4.3  Cervical cancer and Cytology  
Cervical cytology smears have been explored by proteomic analysis and intracellular proteins 
from the exfoliated cervical cells have been used as a means of diagnosing invasive cancer 
from normal by using a discriminating pattern of seven proteins with a sensitivity of 87% 
and a specificity of 100%(Wong, Cheung et al. 2004).  Both up regulated and down regulated 
protein peaks were found to be important but the proteins that were found to be useful were 
not identified.  
 
1.2.4.4 Breast Cancer and Nipple Aspirate 
Proteomic analysis of nipple aspirate fluid (NAF) in the diagnosis of breast cancer has been 
shown to yield a high accuracy for the detection of advanced disease (Sauter, Zhu et al. 2002; 
Coombes, Fritsche et al. 2003). The reproducibility of SELDI-TOF proteomics has been 
demonstrated by analyzing fluid from the same women over several days.  A prospective trial 
that collected nipple aspirate fluid from 114 women undergoing diagnostic breast surgery 
aimed to determine protein masses associated with breast cancer whether or not there were 
any subsets of women with a unique proteomic profile and if this could be developed into a 
breast cancer predictive model.  They concluded that the best cancer detection model 
included age, parity and the presence or absence of a 11,880 Da protein(Sauter, Shan et al. 
2005).  
1.2.4.5 Renal Cancers and Urine 
Urine has been found to be of value in the diagnosis of urothelial malignancy(Celis, Wolf et 
al. 2000).  Celis et al identified SELDI-TOF proteomic strategies that were used to identify 
metaplastic lesions in bladder squamous cell carcinomas, as well as biomarkers in the urine 
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for follow-up studies of patients with carcinoma. Renal cancer is often detected incidentally 
and is frequently advanced at the time of presentation with over half of patients having local 
or distant spread.  Urine samples from patients before nephrectomy for renal clear cell 
carcinoma (RCC), from normal volunteers and  from outpatients attending with benign 
diseases of the urogenital tract were successfully used to develop normal and diseased 
discriminating  SELDI spectra (Rogers MA 2003). This was based on either the presence or 
absence of peaks or altered peak intensity values, resulting in sensitivity and specificity values 
of 98.3 and 100%.  Work has also been done on serum in RCC patients, where the proteins 
have been identified as haptoglobin 1-  and serum amyloid  -1  and an as yet unidentified 
marker(Tolson, Bogumil et al. 2004).  
1.2.4.6 Monitoring Treatment Response 
In addition to the large body of work accumulating on diagnosis there is interest in using 
proteomic technology to examine response to therapy, particularly to chemotherapeutic 
drugs.  In theory, treatment could be monitored by examining the proteomic profiles of 
serum both pre- and post-chemotherapy. The development of resistance to chemotherapy is 
thought to be caused by alterations of proteins within the cell. For example proteins 
associated with Vinca alkaloid resistance have been identified in human leukaemia cells by 
proteomic analysis (Verrills, Walsh et al. 2003) and in breast cancer patients undergoing 
chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide, a single 
chemotherapy inducible serum protein peak was identified at 2790m/z when it appeared on 
day 3 in 80% of subjects undergoing chemotherapy(Pusztai, Gregory et al. 2004). Women 
receiving paclitaxel chemotherapy both adjuvantly and neoadjuvantly were studied and the 
protein was inducible in 80% of patients who were treated preoperatively and in 
approximately 40% of patients treated postoperatively but there was no clear correlation 
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between induction of the protein and final tumor response to preoperative chemotherapy. 
Five other peaks also were identified that discriminated between plasma from patients with 
breast carcinoma and plasma from normal women. These same peaks also were detectable in 
a subset of patients who already had undergone surgery to remove their tumors, suggesting 
that this could be used as a marker for residual disease.   
In a study aimed at identifying proteases for drug targeting in colorectal cancer(McKerrow, 
Bhargava et al. 2000), tissue samples for 15 patients, one set of samples from the tumour, 
another set from adjacent normal colon and a last set from the liver metastases were 
analysed by SELDI-TOF.  They discovered significant differences using SELDI-TOF in the 
levels of metalloproteases (high in the primary tumour, low in normal mucosa) and in mast 
cell proteases (high in normal mucosa, low in the tumour and absent in the metastases). The 
major proteases detected were metalloproteases; Cathepsin B activity was significantly higher 
in the primary tumour and even higher in the metastases. 
 
1.2.4.7 An Update on SELDI-TOF MS 
In the time since undertaking this research there has been a steady decline in the number of 
SELDI-TOF MS based publications. This is due in part to the evolution of more 
quantitative methods of Proteomics but is also due to the increased awareness of the 
drawbacks of this technique. The initial paper that employed SELDI to detect ovarian cancer 
with 100% sensitivity has yet to lead the development of a screening test for ovarian cancer 
and the results have not been reproduced by others.  
 
The reproducibility of SELDI in different laboratories and also within the same laboratory 
has been studied, one group compared their own results in breast cancer with the published 
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literature and found that they had the same peaks as 25% of the published literature 
(Callesen, 2008). They later performed a reproducibility meta-analysis including their own 
peaks in ovarian cancer and had a slightly higher amount of same peaks (40%) that 
discriminated cancer from controls (Callesen, 2012)  
 
In colorectal cancer there has been ongoing research in serum and also in tumour, adenoma 
and mucosal tissue using both SELDI and other proteomic techniques;  Gelsolin is a down 
regulated protein in colorectal cancer tissue which was identified using iTRAQ proteomics 
(Fan, 2012).   
 
In one very interesting paper serum samples were taken from the same patients (cancer and 
controls) on 8 separate days over 5 weeks and they were not able to identify cancer from 
controls when this variability was introduced (Albrethsen, 2012).  
 
Wang et al had previously published results showing a 95% sensitivity and 95% specificity 
for a panel of peaks. Using the same serum samples that were shown to have previously 
detected peaks they used these samples in a more complex experiment, introducing a third 
group of general cancers and these peaks failed to discriminate CRC from other cancers but 
it was possible to separate normal from all cancers. (Wang, 2009) 
 
Response to chemotherapy in colorectal cancer is attracting interest and predicting a good 
response to chemotherapy may be possible using a biomarker. Apolipoprotein A-I was 
shown to be associated with a good response to oxaliplatin and capectiabine chemotherapy 
(Helgason, 2010). 
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Table 1.7 summarises the recent work done in this field, the peaks are different in each 
study.  
 
Author Year Tissue type Aim of study Peaks/Protein 
Fan NJ 2012 Serum Discriminate CRC 
from other cancer 
741Da* 
7772Da 
Xu W 2014 Cancer, 
ademona, 
mucosa 
Discriminate cancer, 
adenoma, mucosa 
Multiple peaks  
Zhai XH 2012 Serum Discriminate cancer 
form normal 
3900Da 
Fan NJ 2011 Serum Node positive form 
node negative 
3104Da, 3781Da, 
5867Da, 7970Da, 
9290Da 
Lai Y 2008 Serum Discriminate cancer 
form normal 
8908Da, 13707Da 
Table 1.7 Recent studies utilizing SELDI-TOF in colorectal cancer diagnosis. 
 *The peak at 741Da is likely to be due to matrix noise and should not be included in 
analysis.  
 
In spite of the large amount of work done in SELDI-TOF based biomarker discovery in the 
20 years since it was developed, there is not as yet a clinically applicable SELDI derived 
biomarker in use.  
 
2.4 Conclusions 
The field of proteomics is moving very rapidly but although many new technologies have 
been introduced over the past 10 years that have enhanced our knowledge in this field, 
developing a comprehensive library of the human proteome will be a considerably larger task 
than sequencing the human genome.  Mass spectrometry based technology has established 
itself as an indispensable tool for interpreting complex samples but despite success in this 
field there are still significant technical challenges. There is much to commend SELDI-TOF 
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MS proteomic analysis; it is efficient at presenting information from a complex sample and 
interpreting patterns through its software analysis packages.  However, the controversy 
generated by the ovarian cancer biomarker paper by Petricoin et al sounds a cautionary 
note(Petricoin, Ardekani et al. 2002). The reproducibility of SELDI-TOF MS is not 
established and conclusions drawn using proteins or fragments that have not been identified 
must be interpreted carefully.  The other concern is that these proteins are not related to 
individual tumours but are part of the general inflammatory response: the so called 
epiphenomena of cancer(Diamandis 2003). There has been much emphasis on pattern 
recognition tools and matching in SELDI-TOF as it is this that holds they key to biomarker 
discovery (Petricoin, Paweletz et al. 2002) but there is still enough variability to treat any 
results with caution. What is clear from SELDI-TOF spectra is that a panel of up and down 
regulated proteins can discriminate between groups; this is a different concept to the single 
biomarker and even the term biomarker may need to be redefined to incorporate these new 
types of screening tools. 
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3.1 Aim of Study 
 To collect serum and stool from patients with operable colorectal cancer and also 
obtain serum and stool from age and sex matched controls that we have proven do 
not have colorectal cancer (“clean” colonoscopy patients). 
 To store in a database their characteristics and pathology. 
 To develop a method of analysis of stool SELDI-TOF MS and apply this to the 
collected samples. 
 To use SELDI-TOF MS technology to compare the proteomes of the two groups. 
 To analyse colorectal adenocarcinoma and matched normal mucosa using SELDI 
technology and compare this to protein peaks detected in faeces and serum. 
 To assess the future utility of these technologies as a screening tool 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Clinical Methods 
2.1.1 Patient Selection 
Ethical approval was granted from the local ethics committee in accordance with the 
national guidelines on clinical research and sample collection commenced following this 
approval (December 2004). All the samples were obtained from patients after obtaining 
informed consent using the consent forms and information sheets contained in Appendix 2. 
There were two centres involved for collection of cancer samples, Ninewells Hospital and 
Medical School in Dundee and Perth Royal Infirmary in Perth, both part of Tayside 
University Hospitals NHS Trust. and all control samples were collected only from Ninewells 
Hospital. Control patients for this study were selected from patients who underwent a 
colonoscopy as part of the Scottish colorectal cancer screening programme pilot. Patients 
were excluded from the study if they had polyps, haemorrhoids and angiodysplasia.  There 
are over 20 screening colonoscopies carried each month in Ninewells and from December 
2004 to March 2006 patients were asked prior to colonoscopy to return a stool sample if 
they had a normal colonoscopy. 
 
The cancer group was selected from those patients undergoing elective surgery for colorectal 
cancer; we excluded patients with known FAP, HNPCC or inflammatory bowel disease and 
all emergency presentations of colorectal cancer. Also excluded were all patients with known 
metastatic disease either pre-operatively or post-operatively. All diagnoses of colorectal 
cancer were confirmed post-operatively by pathological staging using the Dukes’s 
classification and also the UICC (the International Union Against Cancer) Staging system. 
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2.1.2 Collection and storage of serum samples 
All haemolysed samples were discarded from the study. Samples were all stored under the 
same conditions in the Tayside Tissue Bank, Ninewells Hospital. Serum was spun and 
separated by one of three specialist tissue bank staff within four hours of collection. Blood 
samples were collected in a red topped vacutainer (Serum Tube, Increased Silica Act Clot 
Activator, Silicone-Coated Interior) and were stored at room temperature until processing. 
For the control group, conditions of collection were identical. The blood was collected by 
the same endoscopist each time and was drawn from a vein on the patients upper limb 
through a cannula inserted for the purpose of administering intravenous drugs just prior to 
colonoscopy. Colonoscopy requires cathartic bowel preparation and fasting prior to the 
investigation, 4 sachets of Kleen-Prep, (an oral powder, each sachet contains macrogol 3350 
(polyethylene glycol 3350) 59g, anhydrous sodium sulphate 5.685g, sodium bicarbonate 
1.685g, sodium chloride 1.465g, potassium chloride 743mg) must be taken prior to the test.  
Each sachet is reconstituted in 1 litre of water and approximately 250mL of reconstituted 
solution is taken every 10–15 minutes until all 4 litres have been consumed. This is 
commenced on the day prior to the investigation and the patient is fasted during this period.  
The solution from all 4 sachets should be drunk within 4–6 hours, flavouring such as clear 
fruit cordials may be added if required. Some patients were unable to tolerate such large 
volumes of fluid and for some it was necessary to replace the KleenPrep with Picolax, 
another oral powder which is sugar-free and contains sodium picosulfate 10mg/sachet, with 
magnesium citrate taken at a dose of 1 sachet in 200ml water in the morning (before 8a.m.) 
and a second in the afternoon (between 2 and 4p.m.) on the day preceding the procedure.  
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Cancer serum samples were collected from patients undergoing elective surgery for 
colorectal cancer. The serum samples were drawn when the patients attended for pre-
operative assessment or on the immediate pre-operative day prior to any surgical 
intervention.  The samples were collected by the admitting doctor on the ward or by NH 
and were drawn from a vein in the upper limb, or more rarely through a cannula.  Blood 
samples were collected in a red topped vacutainer (Serum Tube, Increased Silica Act Clot 
Activator, Silicone-Coated Interior). Samples were then taken to the tissues bank for 
processing. 100 control samples and 86 cancer samples were collected.  
 
 2.1.3 Collection and Storage of Control Stool Samples 
Stool samples were collected from patients following a clean colonoscopy result.  In March 
2006 patients who had undergone a normal colonoscopy in the preceding 16 months and 
had consented to be approached for a subsequent follow up stool sample were contacted by 
post and asked to return a stool sample. Samples were collected by the patients themselves in 
a blue universal container and the sample was then returned by first class post. 100 control 
stool samples were collected and 47 cancer samples.   
The samples from cancer patients were collected pre-operatively, at the pre-operative 
assessment clinic the patients were asked to return with a stool sample when they attended 
the hospital for surgery.  These samples were then collected by the patients and were then 
collected from the ward by NH and processed. 
On receipt the samples were mixed with PBS and then the stool was left to stand for 30 
minutes prior to vigorous manual homogenization. The stool saline mixture was then 
aliquoted for storage at -80C in the freezer until required. As all the control samples were 
recruited from a population that had tested FOB positive, the FOB status of each stool was 
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recorded at time of receipt. Most control stool samples were FOB positive, which led to 
them having the colonoscopy. These were used as the control samples as they all were 
proven not to have CRC and so in spite of the postitive FOB were suitable for a control 
group. 
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Part 2 Laboratory based materials and methods 
2.2.1. Solutions and Buffer Recipes 
Buffers were made using reagents from Sigma-Aldrich unless otherwise stated. All de-ionised 
water was supplied by the department of surgery and molecular oncology. TRIzol was 
supplied by Invitrogen 
  
General solutions 
Phosphate buffered saline 
Dissolve 8g of NaCl, 0.2g of KCl, 1.44g of Na2HPO4 in 800ml of distilled water. Adjust pH 
to 7.4 by titrating with HCl, make up to 1 litre with water.  
 
Buffers for SELDI-TOF analysis 
Buffers were made fresh with de-ionised H2O from 1M stock solutions when required. This 
was calculated using the equation C1V1 = C2V2. Buffers were dissolved on a magnetic stirrer 
and pH was obtained and measure using a pH meter. The buffers were stored at room 
temperature and in daylight unless otherwise stated. 
For the Q10 ProteinChip 
Low stringency 50mM TRIS-HCl pH9 
High stringency 100mM Na acetate pH6 
 
To make a stock solution IM TRIS-HCl dissolve 121.1g of TRIS base in 800ml of H2O. Add 
concentrated HCl to the desired pH. Adjust the volume to 1 litre with H2O. 
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To make a stock solution of 1M Sodium acetate dissolve 136.1g of sodium acetate into 
800ml of H2O. Adjust the pH with glacial acetic acid. Adjust the volume to 1 litre with H2O. 
 
For the CM10 ProteinChip 
Low stringency buffer 100 mM Na Acetate pH 4.0 
High stringency buffer 50 mM HEPES pH7 
 
To make a stock solution of 1M Sodium acetate, dissolve 136.1g of sodium acetate into 
800ml of H2O. Adjust the pH with glacial acetic acid. Adjust the volume to 1 litre with H2O. 
To make a stock solution of IM HEPES, dissolve 238.3g of HEPES into 800ml of H2O. 
Adjust the pH to 7.0 with NaOH and adjust final volume to 1litre with distilled H2O.  
 
For the IMAC30 ProteinChip 
Buffer: 100 mM Na phosphate pH 7.0  
Pre-activation buffer 0.1M copper sulphate  
Deactivation buffer 0.1M sodium acetate ph4  
 
To make a stock solution of 1M sodium phosphate, dissolve 142.09 of sodium phosphate 
into 800ml of de-ionised H2O. pH to 7.0 and make the solution up to 1 litre using de-ionised 
H2O. 
To make a 0.1M solution of copper sulphate, dissolve 15.9g of copper sulphate in 800ml of 
de-ionised H2O. Add de-ionised H2O to make up to 1 litre.  
To make stock solution of 1M sodium acetate, dissolve 136.1g of sodium acetate into 800ml 
of H2O. Adjust the pH with glacial acetic acid. Adjust the volume to 1 litre with H2O. 
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For the H50 ProteinChip 
Buffer: 0.1 % TFA 
 
To make a 0.1% solution of trifluoroacetic acid, add 0.5ml of trifluoroacetic acid to 500ml of 
de-ionised H2O.  
  
Sample buffers 
U9 Buffer (9M Urea, 2% 3-[(3-cholamidopropyl)dimethylammonio]-1 -propanesulfonic acid 
(CHAPS) 50 mM Tris-HCl pH 9) 
In 80ml of de-ionised H2O take 54.054g of Urea and add 2g of CHAPS (manufactured by 
BDH) and 6g of Tris-HCl. Carefully pH  to pH9 with HCl and make up to 100ml with de-
ionised H2O. 
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2.2.1.2 Solutions and Buffers for tumour preparation  
HEPES (1M pH7.5)  
Dissolve 28.83g of HEPES in 80ml of de-ionised H2O. Adjust pH with potassium 
hydroxide to 7.5 and make up to a final volume of 100ml with de-ionised H2O. Store at 4C. 
SDS PAGE and 2D PAGE Reagents 
Sample buffer used was a solution of 4%SDS, 20% glycerol, 20mM Tris, 10mM EDTA, 
200mM DTT with bromophenol blue at pH6.8.  
The running buffer used was a solution of 1.92M with 250mM TRIS and 1%SDS. 
Running gel recipe: 4ml H2O, 3.3ml 30% acrylic mix, 1.5M TRIS (pH8.8), 0.1ml 10% SDS, 
0.1ml 10% APS, 4uL TEMED. 
Stacking gel recipe: 3.4ml H2O, 830uL 30% acrylic mix, 630uL 1M TRIS (pH6.8), 50uL 
10%SDS, 50uL 10% APS, 5uL TEMED 
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2.2.1.3 Experiments for optimisation of SELDI-TOF analysis 
Preparation of stool samples for SELDI analysis 
Stool samples were defrosted on ice and then mixed with U9 buffer. The stool and U9 
mixture was vortexed for 30 minutes at 4C prior to profiling on the SELDI chip. 
 
2.2.1.4 Preparation of the ProteinChip arrays  
All chips were processed using these methods on an 8 spot array surface using the Cassette 
Compatible Bioprocessor (Cat. No. C503-0011). 
 
Preparation of the Q10 ProteinChip Array (Strong Anion Exchanger) 
Selection of appropriate binding buffers and sample buffers was performed. The 
ProteinChip array cassette was placed in the Bioprocessor and 200uL binding buffer was 
added to each well, the cassette was covered with parafilm and incubated for 5 minutes at 
room temperature (RT) with vigorous shaking (Micromix setting 20/7).The buffer was 
removed from the wells and immediately replaced with 90uL of binding buffer and 10uL 
sample. This was then covered and incubated for 60 minutes at RT with vigorous shaking on 
the Micromix. Samples were removed from the wells and washed with 200uL of binding 
buffer, with 5 minutes incubation with vigorous shaking on the Micromix again at RT; this 
was repeated for a total of three washes. The buffer was removed from the wells and 200uL 
of deionised water was added to each well and removed immediately, this was repeated once 
for a total of two water washes. The reservoir was then removed from the Bioprocessor and 
air-dried for 20 minutes until dry. Without removing the arrays from the cassette, 0.8uL of 
matrix was added and allowed to dry, a further 0.8uL of matrix was added and then allowed 
to dry.  
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Preparation of the CM10 ProteinChip Array (Weak Cation Exchanger) 
Selection of appropriate binding buffers and sample buffers was performed. The 
ProteinChip array cassette was placed in the Bioprocessor and 200uL binding buffer was 
added to each well, the cassette was covered with parafilm and incubated for 5 minutes at 
room temperature (RT) with vigorous shaking (Micromix setting 20/7).The buffer was 
removed from the wells and immediately replaced with 90uL of binding buffer and 10uL 
sample. This was then covered and incubated for 60 minutes at RT with vigorous shaking on 
the Micromix. Samples were removed from the wells and washed with 200uL of binding 
buffer, with 5 minutes incubation with vigorous shaking on the Micromix again at RT; this 
was repeated for a total of three washes. The buffer was removed from the wells and 200uL 
of deionised water was added to each well and removed immediately, this was repeated once 
for a total of two water washes. The reservoir was then removed from the Bioprocessor and 
air-dried for 20 minutes until dry. Without removing the arrays from the cassette, 0.8uL of 
matrix was added and allowed to dry, a further 0.8uL of matrix was added and then allowed 
to dry.  
 
Preparation of the H50 ProteinChip Array (Hydrophobic chip surface) 
Selection of appropriate binding buffers and sample buffers was performed. ProteinChip 
arrays were placed in the cassette and then into a small bath containing 50% methanol for 5 
minutes at RT. The methanol bath was then emptied and changed and the chips rewashed 
for a further 5 minutes at RT, giving a total of 2 methanol washes. Following this the 
cassette was placed in the Bioprocessor and 150uL binding buffer was added to each well, 
the cassette was covered with parafilm and incubated for 5 minutes at room temperature 
(RT) with vigorous shaking (Micromix setting 20/7).The buffer was removed from the wells 
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and repeated again, for a further five minutes incubation at RT on the Mocromix. The buffer 
was removed and immediately replaced with 90uL of binding buffer and 10uL sample. This 
was then covered and incubated for 60 minutes at RT with vigorous shaking on the 
Micromix. Samples are removed from the wells and washed with 200uL of binding buffer, 
with 5 minutes incubation with vigorous shaking on the Micromix again at RT; this was 
repeated for a total of three washes. The buffer was removed from the wells and 200uL of 
deionised water was added to each well and removed immediately. The reservoir was then 
removed from the Bioprocessor and air-dried for 20 minutes until dry. Without removing 
the arrays from the cassette, 0.8uL of matrix was added and allowed to dry, a further 0.8uL 
of matrix was added and allow to dry. 
 
Preparation of the IMAC 30 ProteinChip Array (Immobilized Metal Affinity Capture) 
Selection of appropriate binding buffers was performed. ProteinChip arrays were placed in 
the cassette and 50uL 0.1M Copper sulphate was added to each well and incubated for 10 
minutes at room temperature (RT) with vigorous shaking (Micromix setting 20/7). The 
copper sulphate was removed from the wells and 200uL of de-ionised water was added to 
each well and incubated with shaking for 1 minute. The water was removed and a 
neutralisation buffer (200uL sodium acetate (pH4)) was added to each well and incubated for 
five minutes at RT on the Micromix. The buffer was removed and immediately replaced 
200uL of de-ionised water which was again incubated for 1 minute at RT. The DI was 
removed and 200uL binding buffer was added to each well which was incubated for 5 
minutes at RT. This was repeated once giving a total of two binding buffer incubations. This 
was then replaced with 100uL of sample (not in a sample buffer), covered and incubated for 
60 minutes at RT with vigorous shaking on the Micromix. Samples are removed from the 
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wells and washed with 200uL of binding buffer, with 5 minutes incubation with vigorous 
shaking on the Micromix again at RT; this was repeated for a total of three washes. The 
buffer was removed from the wells and 200uL of deionised water was added to each well 
and removed immediately, this was repeated once for a total of two DI water washes. The 
reservoir was then removed from the Bioprocessor and air-dried for 20 minutes until dry. 
Without removing the arrays from the cassette, 0.8uL of matrix was added and allowed to 
dry, a further 0.8uL of matrix was added and allow to dry. 
 
Preparation of the All-in-One Protein Standard II 
All-in-One Protein Standard was prepared into 2uL aliquots which were kept in the freezer.  
When required a sample was removed from the freezer and defrosted, the sample was then 
spun in a microcentrifuge to collect the 2uL at the bottom and to this was added 8uL of 
EAM, this was then pipette mixed. 
 
Preparation of the EAM matrix Sinapinic acid 
One tube of Sinapinic acid contains x ug of sinapinic acid, this was made into a saturated 
solution by adding to the tube 100uL of acetonitrile and 100uL of 1% trifluoroacetic acid. 
This was vigorously mixed on a vortex for 15 minutes and then briefly spun in a 
microcentrifuge to pellet any undissolved sinapinic acid.  
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2.2.1.1 Tumour sample analysis  
Samples were supplied by the Tayside Tissue Bank and were taken from freshly removed 
surgical specimens that were frozen immediately following dissection.  Samples are stored at 
-80 C in the tissue banks storage facility. Tumour samples were supplied as a 5mm cube of 
tissue with an equal sized piece of adjacent normal mucosa.  Slides were taken from blocks 
of tumour and adjacent normal colon. 
  
2.2.3 Laser Capture Microdissection 
Tumour sections were taken from blocks of tumour and stained with haematoxylin and 
eosin and fixed onto slides 10 nanometres thick.  They were then stained and dehydrated 
using the Arcturus HistoGene LCM Frozen Section Staining Kit. A total of 7 plastic jars 
were labelled and filled with  
Jar a 75% ethanol 
Jar b distilled water 
Jar c distilled water 
Jar d 7% ethanol 
Jar e 95% ethanol 
Jar f 100 ethanol 
Jar g xylene 
Using the solutions that were supplied with the kit, four slides at a time were processed 
through the staining and dehydration process.  The sections were allowed to thaw for 30 
seconds on a lint free towel.  The slides were placed into 75% ethanol for 30 seconds and 
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then transferred to distilled water (jar b) for 30 seconds. The slides were removed and placed 
on the dry towel. 100uL of HistoGene staining solution was applied to the slide to cover the 
section and this was allowed to stain for 20 seconds. The slides were then placed into a 
distilled water wash for 30 seconds.  The slides were then placed in sequence through 
increasing concentrations of ethanol for 30 seconds each and then finally into xylene for 5 
minutes.  The slides were dried and then transferred into a dessicator. Fresh solutions were 
used for each batch of four slides. They were then examined under the LCM System and a 
cap of 2000 cancer cells was collected along with matched normal mucosa.  In accordance 
with the manufacturers instructions cells were added to 2UL of lysis buffer and the 8Ul of 
PBS was added to make 10Ul of lysate. The tube was inverted onto the cap and then 
centrifuged for 20 seconds at 13k.  Samples were then ready for analysis. They were then 
examined under the LCM System and a cap of 2000 cancer cells was collected along with 
matched normal mucosa. In accordance with the manufacturers instructions cells were 
added to 2UL of lysis buffer and the 8Ul of PBS was added to make 10Ul of lysate.  The 
tube was inverted onto the cap and then centrifuged for 20 seconds at 13k.  
 
Protein extraction from tumour using SIGMA TRI reagent 
Tissue samples were homogenised using the Ultra Turaxx Homogeniser in Trizol (1ml per 
50-100mg tisssue) and allowed to stand for 5 mins at RT to ensure complete dissociation of 
nucleoprotein complexes.  Following this 0.2ml of chloroform per ml of Trizol used was 
added, covered and shaken vigorously and left to incubate for 15 minutes at RT.  This was 
then centrifuged at 12000G for 15mins at 4 C.  The resultant mixture was then in 3 phases, 
red organic (protein and DNA) interphase (DNA) and a colourless upper phase (RNA). 
Remove the aqueous phase and add 0.3ml 100% ethanol per 1ml of Trizol used. This was 
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was mixed and incubated for 3 minutes at RT and then centrifuged at 2000G for 5 minutes 
at 4C. The supernatant was removed for protein precipitation. 
 
Proteins were precipitated from the supernatant with 1.5ml isopropanolol per 1ml of Trizol 
and incubated for 10 minutes at RT, then centrifuged at 12000G for 10minutes at 4C. 
The supernatant was was discarded and the pellet was then washed 3 times in 95% ethanol 
(2ml per 1ml Trizol). Each wash consisted of a 20 minute incubation at RT for 20 and 
subsequent centrifuge at 7500G for 5mins at 4C to pellet the protein. 2ml 100% ethanol was 
then added and vortexed prior to incubation for 30mins at RT. Centrifuge for 5mins at 
7500G at 4C and dry pellet under vacuum for 10 minutes.  The pellet was then dissolved in 
Triton X100 with repeated pipetting and given a final centrifuge at 10000G for 10mins at 4C 
and used immediately. 
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2.2.4  Depletion of serum  
Serum was depleted of albumin, transferrin, Haptoglobin, Anti-trypsin, IgG and IgA, using 
the Agilent high capacity multiple affinity removal spin cartridge. Serum samples were 
defrosted on ice and 14uL was diluted with buffer (named as “Buffer A” in the kit.) to a 
volume of 200uL.  This was filtered through a 0.22um spin filter and collected.  The spin 
column was then prepared by washing through 4ml of Buffer A, excess buffer was removed 
from the top of the resin bed to allow for the filtered, diluted serum to be added. The 
sample was then added and the spin column capped loosely, a collection tube, labelled flow 
through fraction 1 (F1) was attached to the bottom of the collection tube and this was 
centrifuged gently for 1 minute 30 seconds. The cap was removed and 400uL of Buffer A 
was added to the top of the spin column, this was then centrifuged for 2 minutes 30 seconds 
at 100 x g and the flow trough was collected in the F1 tube. The F1 tube was removed, the 
collected flow through was stored and replaced with a fresh collection tube (F2), a further 
400uL of Buffer A was added to the top of the column and this was then centrifuged for 2 
minutes 30 seconds at 100 x g. The collected flow through was stored. The bound proteins 
were then eluted from the spin column resin by slowly pushing 2ml of Buffer B through the  
cartridge and into a fresh collection tube (Bound) and following this elution the spin column 
was re-equilibrated by slowly pushing 4ml of Buffer A through the spin column, this was not 
collected.  The spin column was then re-used or returned to the fridge (4 C) for storage. 
Both the sample tube and the sample were chilled for 30 minutes at 4C.  The sample was 
then mixed with acetone at a ratio of 1:6 and the tube was inverted 3 times.  Following this 
the sample was chilled at -20C and observed carefully for formation of a flocculent which 
occurred between 1 to 4 hours. The sample was then spun at 6000 x g for 10 minutes and 
the acetone was decanted and not allowed to dry. 
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2.2.5 Miscellaneous experiments 
The Bradford Assay  
This is the standard and traditional method of assessing protein concentration of a sample. 
 
Micro Assay Procedure 
The spectrometer was switched on and allowed to warm up for 15 minutes before use. 
Standards were prepared using Bovine Serum Albumin over a range of concentration from 1 
to 20 micrograms of protein to a volume of 200 µl in each cuvette. Unknowns were also 
prepared to estimated amounts of 1 to 20 micrograms protein per tube to a final volume of 
200 µl. 800 µl dye reagent was added to each and incubated for 5 minutes before the 
absorbance at 595 nm was measured and noted down for each standard and each unkown.  
Macro Assay Procedure 
The spectrometer was switched on and allowed to warm up for 15 minutes before use. 
Standards were prepared using Bovine Serum Albumin over a range of concentration from 
20 to 200 micrograms of protein to a volume of 200 µl in each cuvette. Unknowns were also 
prepared to estimated amounts of 20 to 200 micrograms protein per tube to a final volume 
of 200 µl. 800 µl dye reagent was added to each and incubated for 5 minutes before the 
absorbance at 595 nm was measured and noted down for each standard and each unkown. 
When large numbers of samples were being processed simultaneously, the assay was 
performed in a microwell plate and the sample made up to a total volume of 200µl in each 
well. 
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Protein analysis by SDS PAGE 
SDS-Page sample buffer was added to the protein sample and then heated to 95C for 5 
minutes therefore denaturing the proteins. These samples were then loaded onto a 10% 
polyacrylamide gel and resolved by electrophoresis in running buffer in an apparatus at 150V 
for 45 minutes. A control lane containing 2.5uL of prestained, coloured low molecular 
weight markers (check maker) was included. The gels were then fixed in fixing solution for 
10 minutes and then a coomassie stain was added for a further 30 minutes with incubation 
on a rocker at room temperature. When the gels had fully stained, they were de-stained on 
the rocker with several changes of de-staining solution and a small piece of crumpled up 
paper towel to absorb the released coomassie stain. The gels were then dried using the gel 
drying apparatus and photographed using a digital camera. 
  
FOB Testing 
On receipt of the stool sample, an FOB test was performed using one Hemoccult II testing 
kit per sample. As per the manufacturers instructions, a small piece of stool was smeared 
onto both windows covering them entirely and then immediately developed using the Hema-
Chek developer (stabilised hydrogen peroxide in aqueous methanol, Bayer Corporation, IN, 
USA).  The window was then assessed for a colour change from white to blue, indicating a 
positive result. Any amount of blue was assumed to be positive.  
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CHAPTER 3 
ANALYSIS OF COLORECTAL CARCINOMA AND NORMAL MUCOSA 
3.1 Introduction 
Colonic epithelium renews itself every five to six days, and suffers extreme environmental 
stress from intra-luminal contents. Colorectal tumours are acquired through genetic 
mutations that confer a growth advantage to the cell characterised by a change in epithelial 
morphology; from normal into dysplasia, followed by adenoma and through to 
carcinoma(Conlin, Smith et al. 2005). In this mucosa to adenoma to carcinoma sequence 
there is a mutation of several genes which trigger cell proliferation, growth and 
transformation and prevention of cell cycle arrest. These changes are multiple and varied and 
colorectal cancer is molecularly and genetically heterogeneous(Hardy, Meltzer et al. 2000). 
Disturbances in the intracellular proteins may be then translated into changes in serum or 
stool. For this reason, tumours were analysed with SELDI-TOF MS to identify if there were 
any peaks present in the solid tumour that would also be seen in the peak profiles found in 
the serum and stool studies. 
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3.2 Optimisation of method 
Initally, four pieces of colonic adenocarcinoma and matched normal mucosa from the 
Tayside Tissue Bank were used as the optimisation tumours. Samples were prepared by the 
tumour bank who removed samples of tumour and normal mucosa from fresh specimens 
and these were then stored at minus 80 C.   
 
A ccomparison of SELDI profiles obtained by tissue homogenization  
The tumours for homogenization weighed between 0.69g and 1.24g with an average weight 
of 1.01g (when frozen at -80C), the matched normal mucosa weighed between 0.98g and 
1.82g with an average weight of 1.60g.  The optimisation samples (tumour tissue matched 
with normal mucosa) were then prepared according to the protocols.   
Two different buffers were used for sample preparation for the solid tumour and these were 
then compared on different chip surfaces (CM10 at pH4 and pH7 and IMAC30). The CM10 
chip profiles at both the low and neutral pHs were disappointing and this surface was 
discounted as a candidate for profiling (Figure 3.1). 
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Figure 3.1 Sample incubated onto the CM10 chip surface at pH7 and at pH4 did not show useful SELDI 
profiles. The peaks are broad and of very low abundance.  
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The IMAC 30 chip revealed clean spectra and this was investigated further at varying 
concentrations of sample; 10 microlitres, 20 microlitres, 50 microlitres and 70 microlitres 
were incubated onto the chip surface in the buffer. The results of this are shown in Figure 
3.2. An optimal amount of 50 microlitres of sample was decided on and this was used in all 
the experiments, there was no appreciable difference in the mean peak intensities of each 
protein peak at the differing concentrations. 
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Figure 3.2 This figure shows the profiles obtained from two samples of tumour at differing concentrations in 
the binding buffer and two samples of normal tissue at two different concentrations. Varying the amount of 
sample in the buffer did not dramatically impact on the mean peak intensities obtained or the number of peaks. 
The normal sample at 70 microlitres has an increase in the binding of the peak at 6500Da and 12500Da but the 
peaks are present in both the higher and lower concentrations at detectable levels.  
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3.3 Analysis of tumours with matched normal mucosa using the IMAC30 chip 
Following selection of the optimal chip surface, eight tumours from tissue bank were 
compared to matched normal mucosa. All were operative resected specimens and so were 
presumed to be potentially curative at the time of surgery. The details of the tumours 
analysed are shown in Table 3.1 
 
PATIENT SEX GRADE OF 
DIFFERENTIATION 
001 f Well 
002 f Moderate 
003 f Moderate 
004 m Moderate 
005 f Moderate 
006 f Moderate 
007 m Moderate 
008 m Moderate 
Table 3.1 Patient sex and degree of differentiation of the tumours analysed on IMAC chip with matched 
normal mucosa. 
 
The Biomarker Wizard software data analysis package was employed for data analysis. The 
data generated from each chip was imported into one experimental file and the baseline was 
subtracted from each spectrum and all data were normalized with a total ion current between 
1500 to 20000Da using a calculated normalization factor of 1.99. All peaks were then 
detected using the automatic peak detection facility, a ratio of 10 signal to noise was selected 
with a minimum peak threshold of 30% of all spectra. In total 54 peaks were identified as 
being significantly different between the two groups (126 peaks were detected in total). Four 
of these were less than 2kDa and so were assumed to be due to matrix noise.  The mass to 
charge ratios were rounded up to a whole number. The mean peak intensities were then 
rounded up or down one decimal place as were the standard deviations. There were 19 M/Z 
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ratio peaks which were higher in the tumour group and 31 peaks which were higher in the 
normal group (Table 3.2). Comparison of tumour and matched normal mucosa revealed 
differences in both the up and down regulation of protein peaks.  
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MASS TO CHARGE 
RATIO (DA) 
P 
VALUE 
MPI NORMAL MPI TUMOUR 
2023 0.001 4.2 0.6 
2055 0.001 3.2 0.9 
2186 0.001 7.7 2.6 
2205 0.001 2.2 0.1 
2352 0.001 2.9 0.0 
2378 0.012 1.4 0.3 
2486 0.015 4.4 2.6 
2582 0.004 2.2 0.4 
2625 0.015 1.4 1.3 
2735 0.012 2.2 1.4 
2826 0.001 0.0 3.5 
2921 0.031 1.4 2.5 
2971 0.004 3.9 0.9 
2999 0.015 2.8 1.8 
3031 0.001 2.9 0.4 
3093 0.001 18.9 4.7 
3250 0.031 1.5 7.7 
3296 0.012 6.6 4.0 
3359 0.004 5.0 4.3 
3374 0.001 4.1 17.7 
3410 0.001 3.3 6.2 
3444 0.001 3.5 21.1 
3489 0.001 4.5 15.4 
3543 0.001 5.1 2.9 
3563 0.001 4.0 2.0 
3853 0.012 3.7 1.2 
3913 0.001 4.3 1.0 
3944 0.004 2.8 0.5 
4054 0.012 3.5 1.5 
4094 0.012 0.7 2.2 
4126 0.001 1.7 4.1 
4228 0.031 1.4 8.9 
4493 0.012 2.6 1.7 
4753 0.001 2.8 0.8 
4922 0.004 2.8 1.0 
5162 0.001 3.9 0.7 
5261 0.004 5.5 0.9 
5289 0.001 4.9 0.8 
5497 0.001 0.9 4.0 
5686 0.012 1.7 4.2 
5717 0.002 1.5 3.9 
6054 0.001 2.9 0.6 
7565 0.015 10.2 7.6 
7748 0.001 6.3 2.6 
7793 0.001 6.3 1.4 
8056 0.001 9.8 2.5 
8793 0.001 2.7 0.4 
9144 0.001 1.8 0.1 
10853 0.001 0.3 4.4 
16095 0.001 7.5 8.7 
 
Table 3.2 Peaks identified by biomarker wizard as different between the two groups. This table shows the mean 
peak intensities (MPI) for each type and the P values.  The peaks that are upregulated in cancer are shown in 
bold.  
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The profiles were then individually assessed for the presence of double and triple charged 
peaks. There were three peaks which differed markedly between cancer and non cancer. 
Average peak intensity for the 3372Da biomarker was 17.7 in the tumour sample compared 
to 4.1 in the normal mucosa. The average peak intensity for the 3443Da biomarker was 21.1 
in the tumour sample compared to 3.5 in the normal mucosa.  Figures3.3, Figure 3.4, Figure 
3.5 and Figure 3.6 show the SELDI spectra for 8 pairs of cancer and matched normal 
mucosa over different mass ranges.  The biomarker peaks are identified in red in the cancer 
samples. The peaks were not present in all eight of the tumours. The mean peak intensities 
were inspected. Upregulated peaks in the tumour group were of most interest, as these may 
be found in the serum and stool.  
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Figure 3.2 
This shows the peaks detected in the 3kDa to 4.5kDa mass range. The up regulated peaks of interest in the tumour samples, 3374, 
3444 and 3490 Da are circled in the red dotted square. In the normal sample the same three peaks are not present. 
In the mucosa samples, the upregulated peak that is seen at 3093Da is not seen in the tumour samples. 
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Figure 3.3 
This shows the peaks detected in the 5kDa to 7kDa mass range. The peaks of interest are labelled,  in the tumour samples, 5497, 
5686, 5717 Da are present and  in the mucosa samples, the peaks that are upregulated are at 5261 and 5289Da. The area of interest 
is highlighted in the red box. Note that the Y axis scale is labelled differently in he tumour compared to normal (max of 30 
compared to 40). 
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Figure 3.4 
This shows the peaks detected in the 6kDa to 12kDa mass range. The peaks of interest are labelled. In the tumour samples, there is 
a peak at 10854Da and in the mucosa samples, the peaks that are of interest are at 7565 and 8056 Da. The area of interest is 
highlighted in the red box.  
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Figure 3.5 
This shows the peaks detected in the 2kDa to 3kDa mass range. The peaks of interest are labelled. 
In the tumour samples, ,there is a peak at 2826Da that is not present (MPI of -0.4) in the normal 
samples.In the mucosa samples, the peaks that are of interest are at 2023, 2055, 2186, 2205,2352, 
2378, 2486, 2582, Da. The area of interest is highlighted in the red box.  
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3.4 Laser Capture Microdissection combined with SELDI-TOF analysis 
The frozen sections (Pathology Department) for LCM were prepared and dried according to 
the protocol, caps were used to select 1000 cells from both the cancers and normal and these 
were lysed into a buffer. Preparation of the samples on the CM10 chip and the IMAC 30 
chip revealed a disappointing trace and the protein concentration for each sample was 
checked and found to be below the optimal threshold for SELDI profiling.  It was estimated 
that 2000 cells would be required for this method to yield sufficient proteins for analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
93 
 
 
CHAPTER 4 ANALYSIS OF HUMAN SERUM 
 
4.1 Introduction 
Screening for colorectal cancer currently involves a series of gFOB tests and an in vasive, 
expensive colonoscopy that carries a small risk of significant harm from complications. If a 
serum biomarker could be identified that would allow identification of patients with 
colorectal cancer, or even more importantly, those with high risk adenomas then this process 
would be revolutionised to a simple blood test that could reduce the numbers of negative 
colonoscopies considerably. The development of such a test would necessitate the 
identification of a biomarker and subsequent development of an antibody.  
There is a move towards personalised medicine and genomics and proteomics are at the 
forefront of this. Detailed study of an individuals tumour, both genetically and in the 
systemic response is leading to increasingly personalised treatment. How applicable this type 
of information is in the field of screening for cancer where cost, acceptable levels of 
sensitivity and specificity and a proven improvement in public health are paramount remains 
to be seen. Serum proteomics using SELDI-TOF MS requires very small amounts of sample 
at low protein concentrations, in contrast to the traditional methods that require large 
amounts of protein to obtain meaningful results and throughput of samples is relatively high.  
Serum is rich in protein, in the normal adult concentration is 40-70 mg/mL protein, but it is 
dominated by a small number of very abundant proteins; up to 70% of serum is albumin, the 
other major components are transferrin, IgG, haptoglobin, alpha-1-antitrypsin and Ig A. The 
other proteins, are numerous in number but very small in concentration, spanning perhaps 
10 orders of magnitude of concentration. Albumin, is a sticky protein and many smaller 
protein fragments and proteins are bound to it.  
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Pie chart representing the constituent 
proteins in serum Albumin 
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macroglobulin
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Within the “others” group lies all the circulating proteins, enzymes, transport and binding 
proteins, complement and clotting factors (more abundant in plasma than serum) transport 
and binding proteins, proteases, protease inhibitors, cytokines, growth factors, hormones 
and an exhaustive list of intracellular and extracellular proteins, existing in a huge variety of 
precursor and degradation states. This is shown in Figure 4.1. 
In screening for colorectal cancer, it would be ideal to detect early cancers and adenomas 
when the chance of any treatment being curative is the highest. However, when disease is at 
an early stage the systemic effects of the cancer and thus the detectable changes in the serum 
are likely to be low. Any changes that are detectable are likely to be small and multiple and 
SELDI-TOF analysis is well placed to identify these.  
 
 
Figure 4.1 Pie chart showing constituents of human serum 
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4.2 Results 
Samples were collected from the two groups, cancer (n=100) and normal (n=100).  
There were more males than females in the cancer group (71% male versus 29% female). 
The age distribution of the cancer group was older than the screening group, average 4.2age 
of 75.4 years (48 to 79 years) compared to 66.1 years. The majority of patients in the cancer 
group had presented symptomatically and were not screen detected, a number of patients 
approached were excluded from the study post-operatively as they were found to have 
metastatic disease of the liver (n=5) or to have had a benign polyp (n=3). None of the serum 
patients were from the tumour group of samples. 
 
Pathological information on tumours  
The patients recruited into this study included rectal cancers, sigmoid colon cancers, 
descending colon cancers and right sided cancers. There were more rectal cancers than any 
other site (54%). Sigmoid and descending colon cancer accounted for almost a third of the 
group and the remaining cancers were on the right side of the colon (caecum and hepatic 
flexure)  The degree of differentiation varied from 76% moderately differentiated and the 
remaining cancers being either poorly differentiated (19% )and well differentiated (5% ). 
There were no poorly differentiated cancers less than a T3. 50% of right sided cancers were 
poorly differentiated compared to just 18% of rectal cancers and none of the sigmoid 
cancers were poorly differentiated. There were no N0 patients that were poorly 
differentiated compared to 50% of the tumours that were staged as N2.  
Staging of cancers was done by two methods, Dukes and the UICC TNM method. The 
majority of cancers were Dukes C, 26% were C1 and 24% were C2. Only 16% of cancers 
were Dukes A and 34% were Dukes B.  
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4.3 Serum analysis 
Initially a test set of samples was used to optimise the method of analysis, these were the 
first ten consecutive samples collected and were a mix of cancer stages. The controls were 
also randomly selected from the initial control samples collected from within the screening 
programme (age range 50 to 74 years). The protein concentration of 10 normal serum 
samples was measured using the Bradford method and found to vary from 48mg/ml to 
80mg/ml with a mean value of 66mg/ml. The protein concentration of 10 cancer serum 
samples was measured using the Bradford method and found to vary from 36mg/ml to 
76mg/ml with a mean value of 68mg/ml.  Each group contained five males and five 
females.  The control group were all fasting and it is not known how many of the cancer 
group were fasting.  
 
SDS PAGE analysis of serum 
A serum sample was then examined using the traditional method of SDS PAGE and stained 
using coomassie blue. The results are shown in the figure 4.2. There was a large smear from 
the abundant proteins, in particular a protein at 66kDa which was highly abundant and likely 
to be albumin. The limitations of discovering biomarkers using this type of technology can 
easily be appreciated.  Even after depletion of the sample for Albumin, IgG, IgA, transferrin, 
alpha-1-antitrypsin, haptoglobin and albumin the gel was difficult to read and small 
abundance proteins were not visible using this technique as the amounts of protein is too 
small. 
  
  
97 
 
 
                         
 
 
A review of the literature revealed that there were no studies into stool using SELDI-TOF 
technology and that there was little done in the field of proteomics using this sample type. 
Advice was sought from the manufacturer (Ciphergen) who had no experience with stool 
experiments. Conditions and chip surfaces for optimisation were selected. Four different 
chip surfaces were used to perform the optimisation, the H50 chip (strongly hydrophobic), a 
strong and weak cation exchanger CM10 and Q10 and a metal anion immobilized binding 
site chip the IMAC 30 were used with to perform the optimisation experiments. The 
samples were tested individually on each chip surface at a range of compatible pH’s and the 
profiles inspected for quality and number of peaks. The H50 chip gave the most detailed 
profiles over a broad range of mass to charge ratios and this was selected as the optimum 
surface. 
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Figure 4.2 SDS PAGE of crude serum and depleted serum.  
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4.4 Analysis of 10 cancer serum samples compared to 10 normal serum samples on 
the H50 chip optimised for the low molecular weight region 
 
The experiment was initially conducted using 10 cancer and 10 normal samples. The 
ProteinChip software data analysis package was employed for data analysis. The data 
generated from each chip was imported into one experimental file and the baseline was 
subtracted from each spectrum following which all data were normalized with a total ion 
current between 2000 to 20000Da using a calculated normalization factor of 1.99. All peaks 
were then detected using the automatic peak detection facility, a ratio of 10 signal to noise 
was selected with a minimum peak threshold of 30% of all spectra. There were 72 peaks 
greater than 2kDa, identified by the sample group statistics as being different between the 
two groups, of these there were 9 statistically significant peaks.  The standard deviations 
were assessed for each value and those which had the largest standard deviations were 
identified for both cancer and normal groups.  There was a subset of four biomarkers that 
appeared to be particularly significant, had small standard deviations relative to their value 
and separated the data out confidently.  These four markers were at 3364Da, 3434Da, 
3479Da and 3700Da.  The mean peak intensity for each group and their standard deviations 
is shown in table 4.1 and the spectra are shown in Figure 4.3. 
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M/Z P- 
VALUE 
MEAN – 
CANCER 
SD - 
CANCER 
MEAN - 
NORMAL 
SD - 
NORMAL 
3479.1 <0.001 13 19 1.3 1.2 
3364.6 <0.001     4.5 4.2 1.3 0.8 
3434.6 <0.001 18 23 2.1 1.7 
3700.8 <0.001 12 18 1.9 2.7 
2841.9 0.001     0.1 0.3 1.1 2.2 
5223.5 0.002     1.2 0.7 0.7 1.1 
2066.4 0.029  1.0 2.5 0.1 0.5 
3567.8 0.029     0.4 0.8 1.4 1.9 
5782.5 0.035     1.5 1.6 0.5 0.4 
Table 4.1 Discriminant peaks that distinguished between cancer and normal samples. P values, mean peak 
intensities and standard deviations. Highly discriminatory peaks are shown in light grey 
 
 
The other markers identified had very low peak intensities compared to the background 
noise and so were not evaluated. The samples were then pooled and analysed, and the 
profiles shown below in Figure 4.4. The results showed that there was an almost total 
absence of the four peaks in the pooled normal sample although not a significant increase in 
the abundance of these markers in the pooled cancer sample as one might have expected.  
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Figure 4.3 
This shows the peaks detected in the 3kDa to 4kDa mass range that were identified as statistically significant 
between the two groups. The peaks at 3364, 3434,3476 and 3700 are labelled in each sample. A clear difference 
can be seen between cancer and normal with a cluster of peaks that are absent on the normal samples are seen 
in most of the cancer samples.  
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Figure 4.4 
Pooled cancer and pooled normal serum samples over the mass range of interest. The peaks are labelled on 
each sample.  
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 A log of the normalized intensity of the peaks between 3360Da and 3500Da is shown in 
Figure 4.5 and shows a separation of the cancer group from normal.  
 
Figure 4.5 Biomarker wizard plot that shows the logarithim of the normalised intensity of three of the peaks 
that separate cancer and normal. 3.36kDa to 3.52kDa range. 
 
 
The peaks were then used to identify cancer from normal as a screening tool, individually 
and together. Individually the peaks were not a powerful screening tool, the weakest peak 
3479Da identified just 6 out of the 10 cancers. 3364 Da and 3434Da identified 8 out of 10 
cancers and 7 of the 10 were identified using the 3700 Da peak. However, when combined 
the sensitivity was improved, with all 4 peaks idenitifying 9 out of the 10 cancers, a 
sensitivity of 90%. Table 4.2 shows the cancer detection rate of the peaks individually and 
combined. When the normal sample spectras were inspected for the same peaks, there were 
no false positives identified using the 4 peaks, a 100% specificity. One of the cancer samples 
that did not have the typical peak pattern displayed was a node positive cancer. 
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Peak Number of cancers detected Sensitivity 
3364 8 out of 10 80% 
3434 8 out of 10 80% 
3479 6 out of 10 60% 
3700 7 out of 10 70% 
3434 and 3700 9 out of 10 90% 
3364 and 3434 7 out of 10 70% 
3364 and 3434 and 3479 7 out of 10 70% 
3364 and 3434 and 3700 9 ou of 10 90% 
All 4 peaks 9 out of 10 90% 
Table 4.2 Power of individual and combined peaks at identifying the cancer samples. 
 
These results were very encouraging and the same peaks were expected to be shown on 
analysis of the full set of samples. 
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4.5 Analysis of 92 controls compared to 86 cancers using the H50 chip 
The experiment was repeated this time with 86 cancers and 92 normal controls using the 
same conditions and chip surface. The same criteria were used for signal noise and 
stringency of peak detection. There were 8 samples that following the experiment were 
unsuitable for inclusion in the analysis due to error in technique and these were discarded 
from statistical analysis. Table 4.3 shows the peaks that were detected as being different 
between the two groups, peaks less than 2kDa have been discarded. There were 5 peaks that 
were different between the two groups that were significant, these are highlighted in bold 
and were not the same peaks that had separated the cancer and normal patients in the initial 
group of samples. 7901 Da, 8124 Da, 8566 Da, 8799 Da and 17 409 Da were the peaks that 
were of interest.  
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M/Z P value Mean – 
cancer 
SD - 
cancer 
Mean – 
normal 
SD – 
normal 
7901 0.00 5.67 5.99 7.37 4.87 
8566 0.01 19.37 20.59 26.32 21.85 
8124 0.01 10.97 11.02 12.59 8.78 
17409 0.01 4.75 8.08 4.54 5.87 
8799 0.03 20.51 19.16 24.00 15.90 
33592 0.05 1.37 2.78 1.44 2.09 
8669 0.06 19.55 19.15 21.25 14.27 
14181 0.11 3.00 4.18 3.07 3.70 
28303 0.14 7.64 13.15 7.45 12.22 
45163 0.15 0.21 0.26 0.24 0.26 
7758 0.17 18.16 23.01 21.85 22.35 
14689 0.21 2.61 3.32 2.18 1.24 
10255 0.40 2.91 4.28 2.58 2.98 
28139 0.43 4.51 8.61 3.93 7.38 
9303 0.48 11.94 12.35 12.95 13.79 
8921 0.62 42.36 27.59 40.49 23.58 
2342 0.67 4.66 6.89 4.71 5.59 
3308 0.72 5.04 8.03 5.06 6.27 
6827 0.81 4.86 7.64 4.51 5.42 
6623 0.87 22.13 28.83 23.53 25.04 
9143 0.88 15.66 14.26 14.53 12.61 
4456 0.99 8.14 14.24 6.37 10.86 
 
Table 4.3 Peaks that were detected as being different between the cancer and normal samples on analysis of the 
100 normal compared to the cancer. 
 
In this experiment the peaks that were detected were different from the previous experiment 
of ten samples. Additionally there was a change in the amount of the peaks detected rather 
than an absolute presence or absence. This finding is reflected in the logarithms of the 
normalised intensity (Figures 4.6 through to 4.9) that do not show much separation between 
the groups around the X axis. Instead there was an up or down regulation in the presence of 
these peaks.  
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Figure 4.6 Logarithm of the peaks identified at 7900Da and 8124 Da as being significantly different between 
the two groups. MPI for cancer was 5.67 compared to 7.37 for the 7900 peak. MPI for cancer was 10.97 and 
12.5 for normal for the peak at 8124Da. Cancer is the yellow diamond and normal the blue square. 
 
Figure 4.7 Logarithm of the peak identified at 8566Da as being significantly different between the two groups. 
MPI for cancer was 19.37 compared to 26.32 for normal. 
 
 
Figure 4.8 Logarithm of the peaks identified 8799Da. MPI of 20.5 cancer compared to 24 for normal. 
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Figure 4.9 Logarithm of the peak intensities identified at the 17409Da peak. The MPI of cancer was 4.7 and 4.5 
for the normal group. 
 
The experiment was repeated and the profiles individually inspected for the four peaks that 
had so confidently separated out from cancer from the controls. The peaks were not present 
in significant numbers of samples and the peaks identified in the experiments were not 
reproducible between experiments. In order to reduce sample complexity it was decided to 
deplete the samples of the major serum proteins to unmask potential biomarkers that were 
not being bound due to competition from the more abundant molecules. 
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4.6 Analysis of serum on the H50 ProteinChip following serum depletion 
Crude serum was taken and fractionated to remove the high abundance, large proteins and 
this was analysed using the H50 ProteinChip. The sample was split into Fraction1, Fraction 
2 and a third fraction, the eluted bound proteins. The SELDI spectra for the high molecular 
weight range (50000Da to 200000Da) can be seen in Figure 4.10.  
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Figure 4.10 High molecular weight SELDI profiles of crude serum, fraction 1 depleted serum, fraction 2 
depleted serum and eluted bound proteins. In crude serum there are few peaks. In the same sample the first 
eluted fraction is much as crude serums, on the second pass through the spin column the peaks are absent. 
When the proteins are eluted from the binding beads and the sample re-analysed the peaks are obviously seen. 
 
Figure 4.10 shows that albumin (66000Da) is present in large quantities on the bound eluted 
protein fraction. Transferrin (90000Da), IgG (150000Da) and IgA (150000Da) are also not 
seen to be bound to the chip when incubated as crude serum and yet do bind when they are 
incubated as an eluted fraction. There are large amounts of each protein in the bound group, 
Albumin 
Immunoglobulins 
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reflected by their large peak intensities compared to the crude sample group. The peak 
profiles for the fractions that had been depleted of the large proteins were not detailed over 
the high mass range and there was little binding of proteins of this size.  
 
The SELDI spectra for the low molecular weight range (2000Da to 70000Da) can be seen in 
Figure 4.11. Fraction one and the crude serum are very similar in their peak profiles, 
following the second run to create fraction two the MPI of each peak decreases significantly 
and there is not a corresponding rise in the number of peaks as was hypothesised. The 
depletion of serum revealed that rather than more detailed spectra being uncovered by this 
technique, the reverse was true and that depletion of the large proteins resulted in almost an 
absence of peaks on SELDI analysis. 
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Figure 4.11 Low molecular weight SELDI profiles of crude serum, fraction 1 depleted serum, fraction 2 
depleted serum and eluted bound proteins 
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111 
 
 
4.7 Comparison of peaks in serum with those found in tumour 
 
The peaks that had been detected in the tumour SELDI analysis that had proved of most 
interest were compared to those found in the serum (Table 4.5). Only one peak was within 
10 Daltons of a peak that had been detected in each sample type, 3444 in solid tumour and 
3434 in serum.  
 
SOURCE MASS TO CHARGE RATIO (DA) 
Tumour derived peaks 2826, 3374, 3444, 3490, 5497, 5686, 5717, 
10854 
Serum sample peaks 3364, 3434,3479,3700 
7901, 8566,8124, 8799, 17409 
 
Table 4.5 Peaks detected in tumour compared to those that were seen in serum. 
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CHAPTER 5 ANALYSIS OF HUMAN FAECES 
SELDI-TOF analysis of cancer versus normal5.1 Introduction 
 
5.1 Introduction 
Composition of stool 
Stools are accessible and despite the huge variety in diet and lifestyle between individuals 
they may represent a source of new colorectal cancer screening biomarkers. The content of 
an average 750g stool is 75% water, the rest being made up of undigested fibre and cellulose 
and other roughage with a rich mix of salts, mucus, bile, stercobilinogen and cells; both 
endogenous and bacterial. The large intestine is a site of intense protein turnover, on average 
12g of protein rich material (0.5g to 4g total nitrogen) enters the large intestine each day 
mainly in the form of protein and peptides (20 - 30%). Dietary sources account for about 
50% of this protein material, the rest is in the form of endogenous proteins; pancreatic 
enzymes, sloughed off cells and mucus(Hughes, Magee et al. 2000).  
Stool is a complex and rich source of compounds and proteins and has not until now been 
examined using SELDI-TOF MS. Utilising this novel technology a method of examining 
stool was developed and this was then employed to analyse the stools of 47 cancer patients 
and 100 control subjects with normal colons.  
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5.2 Results 
Samples were collected from the two groups, cancer (n=47) and normal (n=100). These two 
groups were then subdivided depending on whether or not the original sample had tested 
positive for occult blood. In total there were 47 cancer samples collected and 45 of these 
were found on rehydration and FOB testing to be FOB positive. This gave four sample 
groups, positive cancer (n=45), negative cancer (n=2), positive normal (n=22) and negative 
normal (n=78).  
Measurement of protein concentration in stool samples 
The stool samples used ranged in weight from 5g to 45g. Measurement of the protein 
concentration was carried out on five samples in each group using a Bradford assay and was 
found to be an average of 0.8mg/ml for the normal samples and 0.35mg/ml for the cancer 
samples.  
 
Sensitivity of the Haemoccult II test  
There were 47 cancer samples collected and of these patients 45 of them (95.74%) tested 
FOB positive. This gives an estimated sensitivity for the FOB as 96%.  The number of 
positive FOB tests in the control group was 22 out of 100.  
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5.3 SELDI-TOF analysis of stool 
 
A technique of analysis was developed after reviewing traditional proteomic methods of 
faecal protein identification. It was first necessary to establish that SELDI-TOF MS analysis 
of stool was possible and samples that were obtained from normal patients were used in the 
initial development of stool SELDI analysis. Despite the protein concentration being below 
the recommended levels, initial experiments showed that profiles could be achieved using 
faecal fluid samples from stool, optimisation experiments were carried out using stool from 
3 normal samples (FOB negative)  and 3 cancer samples (FOB positive) on different chips 
surfaces and using different binding buffers. The IMAC 30 chip and the CM10 and Q10 
chips were selected at varying pH concentrations (pH4, pH5, pH6 for the CM10 chip and 
pH 7,pH8, pH9 for the Q10) (Figure 5.1). The number of peaks present in the profiles, as 
well as any differences between the peaks in the two groups were noted. Additionally the 
profiles were visually assessed for quality. Following this the optimum conditions for 
expression difference profiling were selected. The CM10 chip using buffers at pH4 was 
selected as the optimal profiling surface as this gave the best spectra.  The quality of the 
profiles achieved is less than what is seen in serum analysis, with fewer peaks, more 
background noise and broader and less well defined peaks.  
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Figure 5.1 Chip surface and buffer conditions used for optimisation of stool method. The 
profiles obtained on the CM10 chip at pH4 were shown to be most detailed. 
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Seven experiments were then designed and carried out on the CM10 chip at pH4 using the 
same spot protocols each time. The number of FOB negative cancer samples was small 
(n=2). 
 Cancer (n=47) compared to Normal (n=100) 
 FOB positive (n=67) compared to FOB negative (n=80) 
 FOB positive cancer (n=45) compared to FOB positive normal (n=22) 
 FOB positive cancer (n=45) compared to FOB negative normal (n=78) 
 FOB negative cancer (n=2) compared to FOB negative normal (n=78) 
 FOB negative cancer (n=2) compared to FOB positive normal (n=22) 
 FOB positive cancer (n=45) compared to FOB negative cancer (n=2) 
 
5.3.1 Comparison of SELDI stool profiles between cancer and non cancer controls  
Two bioprocessors were used to analyse the 147 samples, using internal calibration. The 
profiles had their base line subtracted and were visually inspected for quality and outliers and 
then normalised. There were 11 normal profiles removed from the analysis as they were not 
of sufficient quality. Highly stringent selection criteria were used, peaks selected were present 
in 50% of profiles.  There were 76 peaks identified between the two groups, 6 were less than 
2kDa and so were not considered in further analysis.  There were 11 peaks that were 
significantly different between the two groups, they are shown in the table 5.1. 
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MASS TO 
CHARGE 
RATIO 
(DA) 
P 
VALUE 
MPI 
NORMAL 
MPI 
CANCER 
3437 0.043 13.4 4.8 
3521 0.043 5.6 0.6 
3574 0.043 6.1 0.0 
3973 0.021 9.0 2.5 
4633 0.021 3.1 19.4 
9801 0.021 5.0 0.0 
10838 0.021 7.6 1.4 
16511 0.043 1.3 5.9 
33423 0.021 0.1 0.7 
37087 0.021 0.0 0.4 
47026 0.043 0.0 0.5 
  
 
 
 
The peaks at 16511Da and 33423Da were confirmed to be the same molecule occurring as a 
dimer. Each peak was then inspected across the spectra and visually assessed. Dimer peaks 
were identified and removed, this is done by a software tool that is built into Ciphergen that 
can compare two peaks and identify if they are dimers; a peak at 60000Da and a peak at 
120000Da can represent two albumin proteins stuck together.  There were 6 peaks that had 
higher values in normal stool sample compared to the cancer stool samples and 5 peaks 
where there was an abundance in the cancer stools. In particular, there was a peak at 4663Da 
which was considerably higher in the cancer group than in the normal (MPI 3.1 versus 19.4). 
The peaks that were increased in the stool of the cancer patients were then compared to the 
known peaks that had been detected in the tumour samples but there were no peaks that had 
been detected in the tumour profiling experiment that were detected in the comparison of 
cancer versus normal (Table 5.2).  The peaks that were upregulated were then used as a 
 
Table 5.1. This shows the peaks detected by biomarker wizard that were significantly different 
between normal control stool samples and cancer stool samples. The peaks highlighted in bold 
were up regulated in the cancer samples. 
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screening tool, using all the peaks and also individually to differentiate the cancer samples 
from the controls. The dimer peak of 16511 and 33423 were treated as one peak.  
 
 
PEAK NUMBER OF CANCERS 
DETECTED 
SENSITIVITY 
4633 37 out of 47 78% 
16511 27 out of 47 57% 
37087 32 out of 47 68% 
47026 16 out of 47 34% 
4633 and 16511 37 out of 47 78% 
4633 and 37087 37 out of 47 78% 
4633 and 47026 37 out of 47 78% 
4633 and 47026 and 37087 39 out of 47 83% 
All 4 peaks 39 out of 47 83% 
Table 5.2 The power of individual and combined peaks that identify cancer samples from normal. 
 
5.3.2 Comparison of SELDI stool profiles between FOB positive and FOB negative 
patients  
Two bioprocessors were used to process the FOB positive stool samples (n=67) and the 
FOB negative stool samples (n=80) with internal calibration. The spot protocols used were 
the same as for the cancer and normal experiment. The difference between an FOB positive 
profile and an FOB negative profile was obvious and is shown in the gel view of two 
samples in Figure 5.2.  
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Figure 5.2 Gel view of an FOB positive trace versus an FOB negative trace. There are two dark and distinct 
peaks visible around the 15kDa region. These peaks are in keeping with the and chains of haemoglobin. 
 
 
There were 37 peaks identified by the biomarker wizard using the same 50% peak presence 
rates. At the less than 2kDa range 5 were discarded as being due to matrix noise, only 4 were 
statistically significant between the two groups. (Table 5.3) 
 
MASS TO CHARGE 
RATIO 
(DA) 
P 
VALUE 
MPI 
NORMAL 
MPI 
CANCER 
2228 0.02 1.9 4.2 
15152 0.01 6.2 14.7 
15894 0.01 1.0 12.3 
29287 0.04 0.6 0.1 
 
Table 5.3 This shows the peaks detected by biomarker wizard that were significantly different between FOB 
positive samples FOB negative stool samples. The peaks highlighted in bold were up regulated in the cancer 
samples. 
 
These peaks were compared to the peaks that were identified in the tumour experiment and 
there was no correlation between these peaks and the ones expressed from the tumour.  
Analysis of the data revealed that there were 7 FOB negative patients that had small peaks at 
the 15kDa range.  These samples that had tested as FOB negative but appeared to have a 
profile similar to the FOB positive samples and so were retested in a separate experiment to 
eliminate the possibility of contamination. SELDI analysis confirmed the initial findings and 
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the peaks persisted at 15kDa, they are clearly identifiable on the spectra. This eliminated the 
possibility of contamination of the samples during the initial comparison. Figure 5.3. 
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Figure 5.3 Gel view of the re analysis of the FOB negative normal samples that have peaks at 15kDa 
 
5.3.3 Comparison of FOB positive cancer (n=45) and FOB negative normal (n=78) 
samples  
In this experiment two bioprocessors were employed with internal calibration to compare 
the FOB negative normals and the FOB positive cancer groups. These were compared using 
the Biomarker wizard and a panel of 6 significant peaks were identified.  Peaks at 5135Da, 
6334Da, 7929.5Da, 15130 Da, 15879Da and 66010Da were significantly different between 
the cancer positives and the normal negatives these are shown in table 5.4. Comparison was 
made with the peaks identified in the tumour experiment and there was no correlation 
between these peaks found to be of significance separating FOB positive cancer and FOB 
negative normal and the ones expressed from the tumour.  
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MASS TO 
CHARGE 
RATIO 
P VALUE MPI 
+CANCER 
MPI 
-NORMAL 
5135 0.01 24 2.7 
6334 0.02 55 25.1 
7929 0.02 12 3.34 
15130 0.03 9.6 1 
15879 0.03 13 3.03 
66010 0.03 16 3.97 
 
Table 5.4 Statistically significant peaks that differentiate between cancer FOB positive and 
normal FOB negative samples that were upregulated in the stool of cancer patients. The 
mean peak intensities are shown for each. 
 
 
5.3.4 Comparison of FOB negative cancer (n=2) and FOB positive normal (n=22)  
There were only 2 FOB negative cancer samples in this study which limited the application 
of statistical analysis of these groups. Using one Bioprocessor and internal calibration the 
samples were analysed. Using values greater than the mean peak intensities for FOB positive 
cancer at 4633, 16511, 33423, 37987, 47026 Da and values less than the mean peak 
intensities of the down regulated peaks in all cancer at 3437, 3521, 3574, 3973, 9801 and 
10838Da it was possible to identify the two cancer samples as belonging in this group.  
 
 
5.3.5 FOBt positive cancer (n=45) and FOBt negative cancer (n=2) 
The limitations in this comparison again related to the small number of FOBt negative 
cancer samples. Analysis of the samples of the FOBt positive cancers using the peaks 
previously identified in the FOBt positive samples compared to the FOBt negative samples 
was undertake and these peaks (5135, 6334, 7929, 15130, 15879, 66010) were not seen in the 
FOBt negative cancers. 
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5.3.6 FOB negative cancer (n=2) and FOB negative normal (n=78) 
This experiment compared the 2 FOBt negative cancers with the FOBt negative normals.  
Due to the difference in sample sizes, the peaks that had previously been found to 
distinguish cancer from normal were used as a screening tool. Using this panel of peaks it 
was not possible to identify the two cancer samples as belonging in this group.  
 
5.3.7.FOB negative normals (n=22) and FOB positive normals (n=78) 
FOB positive normals and FOB negative normals were not compared in one experiment, 
therefore the peak profiles were taken from two experiments to allow comparison of these 
groups. This is a less valid method of comparison as results are affected by processing in 
separate experiments. However, the peaks that were significantly different between the 
groups were likely blood proteins, all around the 15kDa size. This finding is difficult to 
interpret without repeating an experiment to allow a direct comparison. The table below 
shows the MPI for the negative and positive groups and the standard deviations. There was 
less standard deviation in the negative FOB samples, although there were peaks that were 
FOB negative on testing that showed small peaks at 15kDa suggesting a sub-FOB detectable 
positivity that was seen by the mass spectrometer.  
 
M/Z p Mean - 
negative 
SD – 
negative 
Mean - 
positive 
SD - positive 
14088 0.01 1.79 1.48 7.99 4.21 
14711 0.01 2.27 0.35 7.17 5.34 
15147 0.01 6.56 3.57 31.89 4.77 
15344 0.01 2.32 1.96 21.91 6.01 
15554 0.01 0.86 1.27 9.72 2.35 
15894 0.01 5.76 2.78 30.78 6.14 
 
Table 5.5 Significant peaks that were detected between FOB positive normals and FOB negative normals. The 
peaks are all around 15kDa, as the profiles have been taken from 2 experiments it is difficult to conclude much, 
the variation around the 15kDa point may represent this variability. 
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5.3.8 Samples may have degraded over time following storage  
In this experiment samples that were collected in the initial optimisation were defrosted and 
incubated on a chip surface under the same conditions as their initial analysis. The amount 
of detail in the spectra in the samples older than one year was seen to be less than that of the 
younger samples and this is shown in Figure 5.6. As samples were stored at -80 C in a 
controlled environment, degradation seems an unlikely source of the variability, and this may 
represent the change in results with SELDI profiling over time, one of the criticisms of this 
technique being intra-laboratory as well as inter-laboratory variability. 
  
124 
 
 
5000 10000 15000
5000 10000 15000
 
001 November 2004
001 August 2006
002 November 2004
002 August 2006
003 November 2004
003 August 2006
0
10
20
30
40
5000 10000 15000
0
10
20
30
40
5000 10000 15000
0
10
20
30
40
5000 10000 15000
0
10
20
30
40
5000 10000 15000
0
10
20
30
40
5000 10000 15000
0
10
20
30
40
50 10 15
 
 Figure 5.6 SELDI-TOF spectra achieved are altered following storage of 21 months at -80 
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5.4 Comparison of peaks in stool with those found in tumour 
The peaks that had been detected in the tumour SELDI analysis that had proved of most 
interest were compared to those found in stool (Table 5.5). The peak at 10838 in the stool 
samples was down regulated in cancer and a similar sized peak at 10854 is found to be 
present in tumour.   
 
SOURCE MASS TO CHARGE RATIO (DA) 
Tumour derived peaks 2826, 3374, 3444, 3490, 5497, 5686, 5717, 
10854 
Stool sample peaks Up regulated in all cancers: 
4633, 16511, 33423, 37087, 47026 
Down regulated in all cancers: 
3437, 3521, 3574, 3973, 9801, 10838 
Upregulated in all FOBt positive cancers: 
5135, 6334,7929, 15130, 15879, 66010 
 
Table 5.6 Peaks detected in tumour compared to those detected in stool samples. 
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CHAPTER 6 
DISCUSSION 
 
This research was undertaken from 2006 to 2008 using what was at that time, a truly novel 
and promising technology. A landmark paper in the Lancet in 2002(Petricoin, Ardekani et al. 
2002) had shown that using SELDI they were able to discriminate between ovarian cancer 
and other benign gynaecological disease with  100% sensitivity and  a 98% specificity. The 
resulting media attention resulted in a US congress resolution urging more research in this 
field. This paper was then widely criticised by many traditional mass spectromitists and was 
subject to a lot of debate but in spite of this many people began using this technology as an 
avenue of biomarker discovery. It was promoted as a high throughput and high sample 
complexity method of proteomics compared to traditional methods of multi dimensional 
gels which could analyse only one sample at a time. Over the last decade, the field of 
proteomics has moved on and SELDI-TOF technology has not heralded a new era of 
personalised medicine and easy to discover highly specific and sensitive tests for cancer and 
other diseases. More sophisticated methods of proteomic analysis have overtaken it, allowing 
quantitative and more reproducible results to be obtained. SELDI may have a role in looking 
at evolving changes in the proteome of patients, for example in response to treatments such 
as chemotherapy. 
 
Pre-analytical phase standardization has been found to be crucial in achieving good results in 
proteomics studies as well as collection and handling of the samples following sampling. 
Proteomics is now known to consist of many subspecialty fields, cytoproteomics the study 
of the intracellular proteome and serum subproteomics, the study of circulating 
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microparticles. It is a far broader and more complex field than perhaps was fully grasped 
twenty and even ten years ago.  
Many high profile institutions, for example MD Anderson in Texas have published papers 
retracting work previously published using SELDI-TOF, the perceived differences in cancer 
and non-cancer samples were on re-analysis traceable back to the day that the experiments 
were run, significant results being achieved by varying the day of the experiment. 
Increasingly advanced statistical packages are being used to mine data sets.  
 
The key in SELDI-TOF and all proteomics studies remains that the peaks must be identified 
and evaluated as a biomarker following discovery. 
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6.1 Study Design and Sample Collection 
Funding for this work had been secured prior to commencing the project; the initial 4 
months were taken up with reviewing the literature which was carried out in 2 parts, a review 
of screening for CRC and SELDI-TOF as a platform for biomarker discovery. 
After becoming competent at basic laboratory techniques (tissue culture, protein 
quantification, gel preparation, making stock solutions) and then attending a training course 
run by Ciphergen in order to use the machine, the main body of work was begun. During 
this time ethical approval was sought. Sample collection could then begin and work on 
tumour analysis and a method of analysing stool samples was developed.  
Initially we hypothesised that the proteins that we might detect in the stool or in the serum 
may perhaps be present in the tumours themselves. Also, this was a way to gain experience 
with the technique and how to optimise conditions for analysis and use the statistics. 
This revealed markedly different spectra between cancer and normal and following further 
review of the literature, it was decided to try and combine LCM with SELDI as this was a 
purer sample as there is no contamination by connective tissue and other cells. The literature 
has many studies comparing 5 tumours with 5 areas of normal tissue, the reason for this 
being that you need at least 2000 individually dissected cells to achieve an adequate amount 
of protein to get just usable spectra. This was prohibitive from a time point of view as to 
dissect 2000 cells for one spot takes many hours of work.  
 
In designing this study sample collection and handling were considered carefully.  When 
planning the number of patients and samples to include it was not possible to use a 
traditional power calculation as there is no available power calculation for SELDI profiling.  
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Sample size was justified based on the time available for sample collection and the number 
of cancers that were seen each week in Ninewells Hospital. 
 
Stool sample collection proved one of the most difficult aspects of this project, collection 
was performed for the cancer group over a 10 month period and despite best efforts to 
recruit as many patients as possible, the initial anticipated number of 100 cancer samples was 
not achieved.  Many of the cancer samples were collected pre-operatively when patients were 
undergoing bowel preparation.  This resulted in a sample that was very high in water content 
and many of these contained too low levels of stool to give a usable profile and so were 
excluded from analysis. Other reasons for the failure to collect a larger number of stool 
samples included; samples wrongly being sent to the laboratories for microbiological testing 
for microbiological testing, patients forgetting to collect the samples and samples going 
missing from the ward.  
 
The control stool samples were of higher quality in terms of the amount and were of normal 
consistency but as they were mailed in samples of fresh stool the age of these samples, what 
storage conditions and transport conditions were like for each was not known.  None 
exhibited any macroscopic mould or bacterial overgrowth.  Although this method of sample 
collection presented a greater degree of variation for each sample it is also the basis of the 
current screening programme and so was used as it was already known to be acceptable to 
patients.  This time delay may account for some variation between the samples. 
 
The control patients were recruited from the screening programme and so do represent a 
selected group of patients in that they were all recently FOB positive. Some patients 
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reported when they were consenting to take part in the study that they were reluctant to 
handle their bowel movements although this did not prevent anyone in the cancer group 
taking part in the study. The amount of stool returned by the control patients was in general 
very low, perhaps as only a small amount is required by the screening programme. In 
contrast the hospital acquired stool samples were usually larger, perhaps as these patients had 
been interviewed face to face and were undertaking bowel preparation.  
 
It would have been challenging to collect fresh stool samples from each group, in particular 
normal controls and to immediately process and store them and this was considered to be 
beyond the resources available. The bowel preparation for colonoscopy within the screening 
programme is usually excellent and although taking the samples at this time was considered 
as a potential source of stool samples it would not have reflected a normal stool. The 
preparation of the samples for SELDI analysis was developed based on methods of stool 
preparation used for traditional proteomic faecal analysis as there was no manufacturer 
protocol or previously published method for this.  Development of this was time consuming 
and initial methods of mixing stool in various buffers in much the same way as serum is 
handled were not successful at obtaining useable spectra.  
 
The quality of the spectra obtained, in terms of the signal to noise ration and the number of 
peaks seen and the amounts of each is less clean than the profiles achieved when examining 
serum and this has perhaps resulted in only the largest and most detailed abundant peaks 
being examined.  Perhaps with techniques of sample fractionation or pre analysis processing, 
cleaner peaks could have been achieved. In particular, the samples could have been 
dehydrated and then rehydrated as a more concentrated solution of protein. 
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It was possible to better control the variables in the collection of serum, the control samples 
came from patients undergoing screening colonoscopies.  They were all fasted pre 
procedure, had undergone the same bowel preparation and had proven normal colons. 
Fasting itself produces a metabolic response and this has been extensively studied in the 
medium and long terms; there may be changes in the serum proteome during the period that 
the colonoscopy group are fasting. Cancer serum samples were collected pre-operatively at 
pre-admission clinic or on the ward prior to theatre, some were fasted but most were not. 
This level of homogeneity within the control group is perhaps a disadvantage as it does not 
reflect the real life conditions that a screening test would need to overcome in order to 
detect disease.  
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6.2 SELDI-TOF MS analysis 
Methods of sample handling, sample preparation for analysis and also how the data were 
handled following analysis in the mass spectrometer all introduced variables into the 
experimental design. Preparation of the array was crucial and the experiments described in 
this thesis were all done manually and not through an automated process. One of the 
disadvantages of manual handling of the samples was that processing of each sample was 
time consuming and so the conditions for each sample on each chip surface were slightly 
different as they may have incubated longer and be subject to more air drying and more time 
exposed to the matrix as well as different lengths of time spent on ice. Methods of 
processing the samples could also have impacted greatly on the results, the selected 
conditions used in the experiments described here were chosen after optimisation which 
identified the most detailed profiles. It is possible that this resulted in a biomarker that has 
not bound to this selected chip surface being overlooked. Additionally, in order to avoid bias 
the samples were not incubated in batches of cancer and normal but were instead spread 
across the Bioprocessor.  Ideally, samples could have been blinded for analysis but this was 
felt to introduce the potential for error in sample handling.  
 
The SELDI machine itself is a further source of variation and requires validation and 
calibration weekly in order to carry out experiments.  Even with this, there is a day to day 
variation in the measurement of the mass charge ratios of standard, known calibrants. It has 
so far not proved possible for groups working in different laboratories to reproduce each 
others results when using SELDI detected peaks. 
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The data produced in a SELDI profile shows clear and detailed peak profiles for the smaller 
molecular weight proteins (below 20 000Da) but above this, even when the machine is 
optimised to show the larger proteins, there are far fewer peaks seen.  This is not in keeping 
with the sizes of many known serum proteins which are generally larger and it seems that 
these proteins are being left out of analysis using this method of proteomics. Additionally, 
the abundance of proteins or protein fragments that are present on a profile do not 
necessarily translate to an abundance in vivo or even in the serum sample itself as this may 
represent instead the protein that binds most efficiently to a given chip at given conditions. 
However, SELDI should be considered as a platform for biomarker discovery and is not 
intended to be a diagnostic tool.  
 
Differing methods exist for analysis of the data that is generated. There are two software 
packages that are marketed by the makers of the machine, one is the integral Biomarker 
Wizard Software that comes with the protein chip reader and provides univariate analysis 
and the other is Biomarker Patterns software which makes a decision tree based, multivariate 
analysis of the data in order to differentiate between two or more groups.  Univariate 
analysis was used in these experiments, utilising the inbuilt biomarker wizard software. 
Multivariate analysis using many layers of decisions and presence or absence of peaks and up 
or down regulation is not likely to lead to development of a screening test as we currently 
know it and seems to be a move away from identification of a single disease biomarker. 
Furthermore a decision tree looking at up and down regulated peaks in SELDI profiles is 
not applicable as a screening tool due to the poor reproducibility of SELDI data when used 
outside of individual laboratories.  
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6.3 Analysis of Tumours 
Using traditional methods of tumour homogenisation, usable and clean SELDI spectra were 
generated, and the differences between the two tissue types were marked with 50 different 
peaks detected. The large number of significantly different peaks between the two groups 
suggests that the samples were representative of their tissue type.  LCM would have resulted 
in only cancer cells and normal cells being compared with none of the surrounding 
connective tissue and blood vessels. Tumour was analysed with LCM and subsequently 
analysed with SELDI-TOF but this proved too time consuming to collect a sufficient 
amount of material to reach the required protein concentration and was not suitable to use 
as a method within the time constraints of this project. 
The peaks identified by the software that were different between the two tissue types were 
multiple as would be expected. Disappointingly none of the peaks that were present in the 
tumour samples were present in the serum samples either in the initial optimisation batch or 
in the larger experiment of all the samples. The same was also true with the stool samples, 
the peaks that were identified did not appear to be the same. Even allowing for 
intervariablity over time with the machine there were not any candidate markers that were 
traceable through tumour, serum and stool.  
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6.4 Analysis of serum 
SELDI-TOF technology has been applied here with variable success, the main problem 
being interassay variability, with peaks that are present in samples that are then absent or not 
as statistically significant on repeat testing.  There was not any demonstrable intra-assay 
variability and the samples that were repeated in triplicate were consistently reproducible. 
This variability could be explained by errors in sample processing; performing the 
experiments on a large scale involved using three bioprocessors and this greatly affected the 
length of time for which each sample was incubated for and the complexity of the 
experiment. It is possible to exclude freeze thaw cycles as a source of error as the samples 
were stored in small aliqots following the initial freeze thaw cycle.   
 
It is hard to ignore the results from the training set as the peaks that were found were 
significant. This pooled sample of serum could be further analysed to identify these peaks 
(using iTRAQ technology for example) and this work is ongoing. By identifying these peaks 
further research could be undertaken to evaluate this result.  
 
The depletion of the major plasma proteins was employed to address this issue, as it was 
thought that by removing the biggest and most abundant proteins this would reveal a 
subproteome of peptides and proteins that were not managing to bind to the limited number 
of binding sites in each chip. Presumably due to the “stickiness” of albumin, depletion of the 
serum did not reveal lots of peaks and the profiles were almost blank.    
 
Human error was initially considered as the reason for the differing results and the large 
experiment was repeated using aliquots of the same samples, this again failed to reveal the 
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peaks that were present in the training set. The collection and storage conditions for the 
samples were consistent and are unlikely to be significant in explaining the results. 
Contamination during the experiment is possible but as the samples were not incubated on 
one cancer chip and one normal chip this seems unlikely.  
  
Testing for CA242, CEA and CA19-9 was not carried out and it is possible that these known 
biomarkers may be present in the samples although there were no peaks seen at the 
molecular weight of these proteins; CEA measures 180,000Da and CA242 is also a very large 
protein of over 200 000 Da.  
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6.5 Analysis of faeces 
Stool samples were collected in universal containers and stored at room temperature as any 
new screening test must be robust.  It was not feasible to devise a method of sample 
collection that would allow immediate storage of samples at -80oC. The Hemoccult gFOB 
test was employed in all stool samples on receipt, in the case of the cancer samples this was 
performed in the ward shortly after the time of collection. The samples were either tested 
prior to the addition of PBS and homogenisation or after when the sample was judged to be 
too dry to sufficiently smear onto the developing window of the testing kit. The control 
stool samples were at least 24 hours old, and likely even older. Only 22 of the samples were 
gFOBt positive (out of 100). It may be that the patients no longer had blood present in their 
stool samples, or it may be that the prolonged transit time has degraded the haemoglobin. 
The samples were collected from control patients up to 16 months following their screening 
colonoscopy.  
The stools were homogenised on receipt and mixed with PBS to obtain a mixture suitable 
for analysis. It may have been more useful to collect the external part of the stool that had 
been in contact with the (distal) colonic mucosa as this may have had more contact with 
potential biomarkers. It is unlikely that this would have made any difference in detecting 
right sided cancers as the stool is liquid on entering the right colon.  
To the best of our knowledge this is the first time SELDI-TOF MS has been applied to 
analyse human faeces. This novel technology has been successfully used here and may have 
implications for research in other conditions of the colon and rectum and may even be 
applicable in proximal gastrointestinal disease. Although not as detailed as the serum 
profiles, the quality of the faecal profiles was adequate to allow analysis. In spite of the 
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hypothesis that intracellular proteins may be actively leaked into the lumen of the bowel and 
be present in the stool samples, this was not reflected in the studies of stool.   
It seems that blood proteins are present in the stool samples and are detected even in those 
samples that tested FOB negative using the Haemoccult, suggesting that SELDI is more 
sensitive than the gFOBt at detecting blood in stool samples.  There were 6 peaks that were 
upregulated in the cancer stool samples and due to the low number of FOBt negative cancer 
samples (2) it is not possible to be sure that these are all blood proteins. The small amount 
of protein that was present in the stool samples prohibited attempts to identify these 
proteins using traditional methods of analysis and the kit available from Ciphergen 
Biosystems (Fremont CA) was also not recommended for faecal protein identification. It 
was anticipated that in the comparison and analysis of stool samples, the degree of variation 
within individuals’ diet may lead to contamination with a large number of exogenous 
proteins from animal sources but the uniformity of the spectra does not support this.  The 
spectra were not as detailed and as clear as the usual SELDI spectra and fewer peaks were 
seen in the stool spectra compared to the tumour and serum derived peaks.  
Peaks that were present in more abundant quantities in the control samples are perhaps 
more difficult to explain but a potential source of this change is that some of the cancer 
samples were collected from patients undergoing bowel preparation and that these samples 
were perhaps more dilute because of this. Another possible explanation may be dietary 
factors.  
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6.6 Overall comparison of peaks  
There was not one peak that was reproducibly seen in tumour, serum and stool. However, 
the variability of SELDI-TOF MS means that some peaks that have values close to one 
another may represent the same proteins, although the significance of these is unclear 
without formal identification. 3444 in the tumour samples was within the margin of error to 
be appearing in the serum as 3434, and there is also the possibility that some of these peaks 
are peptide fragments of larger proteins. Table 6.1 shows the profile peaks that were 
detected in each experiment as significant.  
 
Source Mass to charge ratio (Da) 
Tumour derived peaks 2826, 3374, 3444, 3490, 5497, 5686, 5717, 
10854 
Stool sample peaks Up regulated in cancer 
4633, 16511, 33423, 37087, 47026 
Down regulated in cancer 
3437, 3521, 3574, 3973, 9801, 10838 
Serum sample peaks 3364, 3434,3479,3700 
7901, 8566,8124, 8799, 17409 
 
Table 6.1 Table showing the peaks identified in the tumours, stool samples and serum. The peaks highlighted 
in bold are similar in size. 
 
It was hoped that there would be a peak present in the tumour that would be either secreted 
or leaked into the serum or stool and that this would be identified by SELDI-TOF analysis. 
This was an ambitious and perhaps overly optimistic assumption to make.  
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
Presented in this thesis are several findings that represent future avenues of exploration in 
the hunt for a novel screening test for colorectal cancer.  During the time that this period of 
research was undertaken, much has changed in our understanding of SELDI TOF MS and 
proteomic technology and the screening programme has reached full national coverage.  
 
Analysis of adenocarcinoma and matched normal mucosa has been carried and there was a 
marked difference between normal mucosa and adenocarcinoma likely to represent highly 
abundant  intracellular proteins. Interestingly, the peaks that have been uncovered here are 
similar in size and charge to those found by another group(Krieg, Fogt et al. 2004).  In spite 
of the hypothesis that intracellular proteins may be actively leaked into the lumen of the 
bowel and be present in the stool samples, this was not detected in out studies of stool.   
 
We are the first to have developed and described a method of achieving acceptable spectra 
using the SELDI technique.  We have shown that blood proteins are present in the samples 
and that these peaks are detected even in those samples that tested FOB negative using the 
Haemoccult suggesting that SELDI is more sensitive than the FOB at detecting blood in 
stool samples.  The profiles generated, although usable were not of high quality and are 
unlikely to lead to further areas of research using this technology.   
 
Analysis of serum using SELDI has shown huge variability in the detected peaks.  Samples 
tested in the initial optimisation on one chip surface present very different results when 
performed on a later date on a larger scale and this variability is problematic when 
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developing a screening test which must be robust. It is concerning that the results are 
variable to such a degree and it may be that the peaks detected do not represent whole 
proteins and are more likely to be fragments of proteins.  
 
SELDI-TOF MS analysis is not applicable as a screening modality but may represent future 
avenues of biomarker discovery and combined with quantitative technologies which have 
less variability and allow for protein identification a new screening test may be found.  
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